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Oesophageal cancer is the most common cause of cancer related deaths among 
black males in South Africa. Currently there are very limited treatment options, and 
patients have a very poor prognosis, due in part to the late stage at which this cancer 
is usually detected. 
In this thesis we describe the establishment of a screening assay using an 
oesophageal cancer cell line as a model. It was our hope that this screen would allow 
us to identify compounds which have activity against oesophageal cancer, that could 
be used as lead agents for further development of chemotherapeutic agents. 
Once our screen was established, we tested a wide range of extracts from southern 
African marine organisms, supplied by our collaborators from Rhodes University, 
South Africa. The marine environment represents a rich, untapped repository of novel 
and interesting compounds, and through our collaboration we had access to a wide 
range of marine-derived extracts and compounds. 
During the course of this project we provided screening data to assist in activity-
directed fractionation from five active marine extracts, giving rise to 15 compounds of 
varying activity. These included several groups of novel active compounds such as 
the makaluvic acids from the sponge Strongylodesma aliwaliensis and the 
malonganenones from the octocoral Leptogorgia gi/christii. The identification of a 
number of novel, active compounds through our screening program highlights the 
potential of marine organisms from the southern African coast as a source of novel 
drug leads. 
We also examined the mechanism of action of a group of triprenyl quinones and 
hydroquinones previously identified from the Arminacean nudibranch Leminda 
millecra by our collaborators. We showed that these compounds cause a cell cycle 
block in oesophageal cancer cells, followed by cell death by apoptosis, and not 
necrosis. The action of these compounds was shown to be a result of their ability to 
produce reactive oxygen species (ROS). Treatment with ROS scavengers decreased 
apoptosis levels in KLM treated cells, and the levels of ROS produced by these 
compounds was directly proportional to their activity (as measured by IC5c analysis). 











KLM155 was demonstrated, and the involvement of AP1 signalling in the cellular 
responses to KLM treatment was examined. 
The production of ROS is an attractive chemotherapeutic approach since recent 
evidence indicates that tumours are under increased oxidative stress, and thus the 
production of ROS may be sufficient to induce apoptosis in cancer cells, while normal 
cells survive. Our results thus indicate that this group of compounds may be good 














1.1 . Oesophageal cancer 
Oesophageal cancer occurs with high frequency in many parts of the world, and most 
often patients have a poor prognosis due to late diagnosis. As this discussion 
highlights, there is a clear need to understand this disease better and improve on the 
treatment options currently available to increase the survival rate of oesophageal 
cancer patients. 
1.1.1. Description 
Tumours of the oesophagus have been classified as 
epithelial and non-epithelial tumours. Of these, 
tumours of the epithelium are the most common , and 
the two predominant forms of epithelial tumours of 
the oesophagus are squamous cell carcinoma (See) 
and adenocarcinoma (1 ;2) . 
WHO classification defines see of the oesophagus 
as "a malignant epithelial tumour with squamous cell 
differentiation, microscopically characterized by 
keratinocyte-like cells with intercellular bridges 
and/or keratinization". see is found predominantly in 
the upper two-thirds of the oesophagus in 85-90% of 
cases (2). Squamous cell carcinoma accounts for 
50-60% of all oesophageal cancer worldwide (3). 
Adenocarcinoma is "a malignant epithelial tumour of 
the oesophagus with glandular differentiation arising 
predominantly from Barrett mucosa in the lower third 
of the oesophagus" (2). Adenocarcinoma accounts 
for 40 to 50% of all oesophageal malignancies 
worldwide (3) . 
Figure 1.1. Location of the oesophagus, 
and the most common sites of 
adenocarcinoma and squamous cell 
carcinoma. 
The most common sites for squamous cell 
carcinoma (See) and adenocarcinoma 
(AC) are indicated. The tumour in the inset 
has constricted the diameter of the 
oesophagus and may interfere with 












Oesophageal cancer is the eighth most common form of cancer worldwide with an 
age-standardised incidence ratio (ASIR) of 11 .5 per 100 000 for males and 4.7 per 
100 000 for females. Oesophageal cancer is the 6th most frequent cancer among 
males, and the 9th most common cancer among females (http://www-dep.iarc.frD. 
The incidence of oesophageal cancer varies widely with geographical location, 
especially when divided into the 2 major forms - squamous cell carcinoma and 
adenocarcinoma. Adenocarcinoma is more prevalent in developed countries, and 
SCC is more prevalent in developing countries, with hotspots in China, South 
America, east and southern Africa, and the Middle East (2) with rates as high as 28.1 
per 100 000 in some areas (http://www-dep.iarc.fr/). 
, . 
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Figure 1.2. Geographical distribution of oesophageal cancer among males. 
Map showing the ASIR of oesophageal cancer among males. Areas of high incidence include 
parts of Asia, the south-east coast of Africa, Italy and France, and a small area in South 
America. (Image from http://www-dep.iarc.frl) 
In South Africa, the predominant form of oesophageal cancer is SCC (1 ;4) with an 
overall ASIR for males of 12.6 per 100 000, and 5.6 per 100 000 for females. 
Considering the high incidence of SCC in South Africa, the work in this project 











common cancer among males (at 6% of all cancers), and the fourth most common 
cancer among women (at 3% of all cancers) in South Africa. While these figures are 
only slightly higher than the worldwide incidence, when incidence is considered 
among different population groups in South Africa, much higher rates are observed. 
Black males are the group most at risk of developing oesophageal cancer in South 
Africa, with oesophageal cancer the second leading cancer affecting black males (at 
14% of all cancers), second only to prostate cancer. The ASIR for this group is 16.2 
per 100000 (4). 
Black females are also at high risk of developing oesophageal cancer with this 
cancer the third leading cancer causing 6% of all cancers after cervical (35% of all 
cancers) and breast (15% of all cancers). The ASIR for this group is 7 per 100000. 
• Incidence 
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Figure 1.3. Cancer incidence and mortality figures for South Africa. 
Oesophageal cancer is among the most common cancers for both males and females in South 
Africa, and the third most common incidence cancer in males, and the fourth most common 
incidence cancer among females . (Image from http://www-dep.iarc.fr/) 
The current 5 year survival rate for patients diagnosed with oesophageal cancer is 
only 14%, which is extremely poor, but is an improvement on the survival rate from 











diagnosis (5), This is due, in part, to improved surgical techniques and earlier 
detection. 
Since this cancer has such high prevalence in South Africa, it presents a high burden 
of disease. Combined with the poor prognosis and late diagnosis, it causes a great 
number of mortalities. As such there is a need for novel chemotherapeutic agents to 
help treat this disease. 
1.1.3. Aetiology 
Whereas adenocarcinoma has been strongly linked to gastric reflux and Barretts 
oesophagus (6), the aetiology of squamous cell carcinoma of the oesophagus is less 
clearly defined. In developed countries there is a strong correlation between smoking 
and drinking, and the risk of developing sec (about 90% in the USA, France and 
Italy), However, in less developed countries the percentage of sce attributable to 
smoking and drinking drops to 50% in South Africa, 20% in Iran, and as low as 1 % in 
Henan province in China (2), Other environmental and behavioural risk factors 
include drinking of extremely hot beverages, low levels of fresh fruit and vegetables 
in the diet, maize as a staple diet and consumption of Fusarium contaminated food 
(often maize) (1 ;2). There is some evidence that infection with Human Papilloma 
Virus (HPV) may be associated with oesophageal cancer, with HPV detected in 15% 
to 75% of oesophageal tumours (7;8). In addition, normal polymorphisms in 
xenobiotic metabolizing enzymes may affect the risk of developing squamous cell 













Oesophageal cancer is staged according to the degree of tumour invasion, 
involvement of regional lymph nodes, and presence of distant metastasis. These 
combine to give 4 stages as detailed in Figure 1.4. At Stage 0, also called carcinoma 
in situ, the cancer is superficial and only involves the innermost layer of cells of the 
oesophagus. Stage I tumours have spread through the epithelial layer and the 
basement membrane to invade the submucosa. Stage II tumours are divided into two 
categories, dependant on the involvement of lymph nodes. At Stage III the tumour 
has invaded all layers of the oesophagus, and may have involved local lymph nodes. 
Stage IV tumours have spread to local or distant lymph nodes (Stage IVA) and may 
have spread to distant tissues (Stage IVB) (11) . 
Cancer 
Figure 1.4. Staging of oesophageal cancer. 
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Oesophageal cancer is staged according to the degree of invasion of the tumour, lymph node 











1.1.5. Treatment options 
If oesophageal cancer is detected early (Stage I and II), the prognosis is favourable, 
and treatment generally comprises of surgery, which is often coupled with 
neoadjuvant chemotherapy (12). However, in most cases, especially in the 
developing world, detection is only at a late stage (Stage III or IV), at which point the 
tumour mass has already invaded surrounding tissue and expanded to fill the lumen 
to obstruct swallowing, and the prognosis is poor (13;14). Due to the poor nutritional 
status of many of these patients, and the involvement of metastases, surgery is not 
the ideal option in most of these cases, and chemotherapy or radiotherapy are the 
options of choice. These may serve to downstage the tumour, allowing surgical 
intervention (12). In some cases, palliative care is the only option, and may comprise 
of chemotherapy, radiotherapy, and intubation (15). 
At Groote Schuur Hospital in Cape Town, South Africa, in the period 1977 to 2003 a 
total of 1895 patients presented with oesophageal cancer. Of these, 42% were not 
suitable for any form of treatment, and received supportive care (16%) and intubation 
(26%). Nineteen percent of the patients received palliative radiotherapy in an attempt 
to decrease tumour size, while only 29% (550/1895) of patients received any type of 
curative treatment. This reflects the late stage at which oesophageal cancer is 
usually diagnosed in South Africa, and the poor prognosis for these patients. Of the 
550 patients receiving treatment of a curative nature, approximately a quarter were 
suitable for oesophagectomy, with neoadjuvant chemo- and radiotherapy. The 
remaining patients received radiotherapy or chemotherapy alone, or combined 
radiotherapy and chemotherapy (equivalent numbers of patients in each group) 
(Personal correspondence, Dr. C. Dandara, University of Cape Town, South Africa.). 
Tew et a/. identified the following reasons for the poor survival rate of patients with 
oesophageal cancer (16): 
i. Poor screening tools and guidelines 
Ii. Cancer detection at a late stage 
iii. High risk of recurrence after surgery or chemotherapy 
iv. Unreliable measurements for response to chemoradiotherapy 
v, Limited survival of patients treated with chemotherapy alone with metastatic 











These can be grouped into 2 main deficiencies in the current approaches -
inadequate identification of patients at an early enough stage to allow treatment (i 
and ii), and a lack of adequate treatment regimes for all forms of the disease (iii, iv 
and v). 
The poor survival of oesophageal cancer patients has been confirmed in numerous 
trials in which various combinations of chemotherapy, radiotherapy and surgery have 
been tested (15; 17-20). The most commonly used and effective treatment for 
oesophageal cancer is a combined cisplatin/5-fluorouracil based chemotherapy, 
coupled with surgery (21). However, some recent trials show some promising results 
with newer agents such as paclitaxel, docetaxel and ironetecan having better activity 












1.2. Chemotherapy for oesophageal cancer 
The most common chemotherapeutic agents used in the treatment of oesophageal 
cancer are a combined cisplatin/S-fluorouracil regime (21). This is a synergistic 
combination with results indicating much higher cell killing in combination, with 
concentrations of each compound that alone cause only minimal cell death (22;23). 
This allows administration of each drug at lower concentrations than required if used 
in isolation, lowering the risks of side-effects. 
1.2.1. C isplatin 
Cisplatin (in combination with S-fluorouracil) is the most commonly used 
chemotherapeutic agent for oesophageal cancer, and is used widely for the 
treatment of various solid tumours (24). 
Cisplatin is a water-soluble planar complex, comprising of a central platinum atom, 
bonded by two chlorine atoms and two ammonia molecules organized in a cis-
conformation. Interestingly, the trans- conformation is far less active (Figure 1.5). 
cisplatin transplatin 
Figure 1.5. The structures of cisplatin and transplatin. 
Cisplatin acts by entering the cell, where the chlorine atoms dissociate leaving a 
reactive complex that can then interact with DNA, causing intrastrand crosslinking. 
There is also evidence that cisplatin damages mitochondria, arrests the cell cycle in 
G2 (probably due to DNA damage), inhibits ATPase activity, and eventually leads to 
apoptosis, inflammation and cell death (2S). 
The major, dose limiting side-effect in cisplatin treatment is nephrotoxicity. Other 
toxicities include ototoxicity, neurotoxicity, and bone marrow suppression. These are 













5-fluorouracil (5-FU) is a member of a class of nucleoside analogues. The fluorinated 
pyrimidines were one of the first groups of successful rationally designed anti-
neoplastic agents, and were synthesized in 1957 (26). 5-FU, the most well known 
member of this class, is a uracil analogue, with a fluorine atom substituted at the 5' 








Figure 1.6. The structures of 5-fluorouracil and related compounds. 
While uracil is normally metabolised into deoxyuridine, and then incorporated into RNA, 
5-fluorouracil is converted into 5-fluorodeoxyuridine, which is then converted to 
fluorodeoxyuridine monophosphate, which binds tightly to thymidilate synthase. 
5-FU alone is known to be toxic to cells via two pathways. The first is by its 
incorporation into RNA as a false nucleotide, which disrupts many cellular processes. 
The second, more immediate mechanism is inhibition of thymidilate synthase. 5-FU 
is metabolized in the cell into FdUMP, which then binds tightly to thymidilate 
synthase. This prevents the normal functioning of this enzyme, which normally forms 
thymidilate, an essential precursor for dTTP. This leads to the depletion of dTMP and 
dTTP, and the inhibition of DNA synthesis and repair. RNA incorporation is a longer-
duration event, and kinetic studies of cultured cells treated with 5-FU indicate that 
there is an initial S-phase block (that could be prevented by dThd), indicative of a 
block of DNA replication, followed by a later period of cell death that could not be 











due to the 5-FU incorporation into RNA, and its effect on RNA processing and 
functioning (27). 
5-fluorouracil is a commonly used therapeutic agent for oesophageal cancer, as well 
as a range of other solid tumours. It is poorly tumour selective, and thus has a wide 
toxicity against normal tissue including bone marrow, gastrointestinal epithelial cells, 
skin, and the central nervous system. Due to its poor selectivity it is often 
administered in combination with other, more selective agents. Side effects include 
gastrointestinal epithelial ulceration, myelosuppression, dermatologic toxicity, ocular 
toxicity, neurotoxicity, cardiac toxicity and biliary sclerosis (28). 
1.2.3. Other chemotherapeutic agents 
Trials using paclitaxel, irinotecan and docetaxel to treat oesophageal cancer have 
shown some promise, with slightly better responses and decreased toxicity in 
comparison to the traditional cisplatin/5-fluorouracil regime (12). However many other 
agents have been tested against oesophageal cancer with no better response than 
the standard 5-FU/cisplatin treatment, and in some cases, higher toxicity. 
A new era in drug development has seen the development of tailored drugs, 
designed to inhibit specific pathways, such as the kinase inhibitor Gleevec (29). In 
the future these tailored therapies would allow an ideal approach for treatment of 
oesophageal cancer patients, with a biopsy of the tumour allowing identification of 
particular pathways that can be targeted in each patient, rather than a standard 
treatment (30) However, unlike the critical alterations/mutations identified in 
leukemia (bcr-abl), the molecular defects associated with the development of 
oesophageal cancer are poorly understood. 
Clearly for the majority of patients the current treatment options are inadequate, and 
there is a need to identify more effective therapeutic agents. Screening programs 
using toxicity against oesophageal cancer cell lines are currently the foremost option 











1.3. Drug Discovery 
1.3.1. Introduction 
The drug discovery process uses many different approaches to obtain new 
chemotherapeutic agents for the treatment of cancer including rational drug design 
and screening. The most traditional, and most successful approach to date (in terms 
of number of compounds identified, and taken to the market) is screening. As our 
understanding of disease processes improves, rational drug design is becoming 
more prevalent (30). 
Compounds identified in conventional screening programs may very well point the 
direction towards new therapeutic target molecules. Many groups are now in the 
process of synthesizing analogues of existing drugs in an attempt to make more 
specific therapies. This combination of the two approaches is more likely to yield 
results than either approach in isolation, as in the case of the development of 17-
AAG (31). 
1.3.2. Rational Drug Design 
Rational drug design exploits the knowledge of a particular enzyme target (generally 
based on the analysis of a protein crystal structure with a substrate molecule bound 
to the active site) in order to design compounds that will interact specifically with the 
target, inhibiting it specifically. Until very recently our knowledge of disease at a 
molecular level was insufficient to allow this. However, with new protein modeling 
techniques, and the elucidation of disease pathways, a number of rationally designed 
drugs have entered the market. 
Unfortunately our understanding of many diseases, cancer in particular, is still too 
limited to allow this approach in more than a few rare examples. A few molecular 
changes have been identified in oesophageal tumours that present potential targets 
for the development of treatments (16). Since many of these changes are shared 
with other tumours, drugs developed as therapies for other cancers may prove 
effective against oesophageal cancer, and vice versa. These potential targets include 
EGFR, Her2/Neu, VEGF and COX2 (16). However, preliminary trials using agents 
targeted for these molecules (developed for other cancers) has not been promising, 











However this will still involve characterization of the target, and design and synthesis 
of potential inhibitors. 
1.3.3. Screening 
Examples of drugs identified by screening are cyclophosphamide (nitrogen mustard 
pro-drug), cisplatin, the vinca alkaloids (from the Madagascan rosy periwinkle 
formerly Vinca rose us, now Catharanthus roseus), doxorubicin (antitumor product of 
Streptomyces peucetius (var caesius)), and Taxol (from the Paciic yew) (32). 
There are several approaches to screening for anticancer agents, based on the 
screening protocol, and the source of the compounds to be screened. The screening 
platform varies from toxicity testing against an entire animal to testing for inhibition or 
activation of a single protein, while compounds can be sourced from synthetic 
libraries, or natural product programs. 
1.3.3.1. Single molecule screening 
This type of screening platform tests compounds against a specific target - for 
example the screens for kinase inhibitors that were used to identify Gleevec (29). 
Compounds identified in this manner need to be carefully validated, first in a cell 
system to show biological activity consistent with that seen in the molecular screen, 
and then in animal systems to elucidate pharmacokinetics and dose effects. It is 
important to bear in mind that the screening target may not be the only, or even the 
most effectively inhibited target by the compound, leading to unexpected side effects. 
Another consideration is that, as in the case of rational drug design, the target needs 
to have been identified, and thus this approach is of limited use in the case of 
oesophagealcance~ 
1.3.3.2. Whole organism screening 
Screening of compounds against an entire organism is seldom performed. In the past 
the brine shrimp assay was frequently used as a measure of toxicity, and is still used 
in some cases, while sea-urchin egg assays are used to identify antimitotic agents. 
There is undoubtably a wealth of information that can be obtained from testing 
compounds in a whole animal system, such as pharmacokinetics, 











screen are outweighed by the expense, time and ethical considerations involved, and 
thus this is better retained as a second or third level validation. 
Traditional in vivo tumourigenesis assays involve injecting tumour cell Jines into 
immunocompromised mice, waiting until a tumour develops, and then treating the 
mice with the compound of interest. 
The NCI has recently instituted a hollow fibre in vivo test for further characterizing 
positive hits in the 60 cell line screen, which is an improvement over the traditional in 
vivo tumourigenesis assay. In this protocol, various cell lines are plated into thin 
tubes (similar to dialysis tubing), and then implanted into the peritoneal cavity of 
mice. The compound of interest is then administered at various doses, and at the end 
of the assay the tubes are removed, and the cell number remaining in the tubes is 
assayed using a conventional MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reagent This allows testing of factors that aren't 
compensated for in cell culture including delivery (blood stream, solubility), toxicity to 
organ systems, pharmacological action (activation/inactivation by metabolic 
enzymes, detoxification kinetics) and side effects (33). 
1.3.3.3. Cell line screening 
The most frequently used screening platform for anti-cancer agents is a cell line 
screen. This is typified by the NCI 60 cell line screen which has been used for high 
throughput screening of natural and synthetic compounds and has been employed by 
a large number of research groups to identify potential lead compounds for cancer 
chemotherapy (34). In the initial years (1960-1982), the NCI screen involved 
assaying for activity against the mouse leukemia cell lines L 1210 and P388. This 
system had several limitations - first, both cell lines were leukemia in source, which 
meant that any agents inactive against leukemia, but potentially active against solid 
tumours would be missed. Secondly, the assay system was murine in nature, and 
thus any compounds targeting human-specific pathways would also be overlooked. 
However the assay was a good indicator of cytotoxicity, and many useful drugs were 
identified, most notably paclitaxel (Taxol) (35). In 1985, the NCI started a new 
program screening extracts against a wide range of human cell lines, covering 
leukemia, colon, skin, breast, ovary, brain, kidney and prostate. This allows the 
identification of agents active against a range of different cancers, as well as yielding 











mechanism of action of a certain compound when compared to the patterns obtained 
from compounds with known mechanisms (34;36). 
Screening against cell lines has advantages over single molecule screens as factors 
such as the metabolism of the compound within the cell can be accounted for. There 
is also the advantage that a specific target does not have to have been identified for 
a particular cancer in order to identify agents that are active against that cancer. 
This approach is also favourable in comparison to screening in a whole animal 
system. However, compounds identified in a cell line screening system still need to 
be verified in a whole animal model, since compounds that are active against a cell 
line may be metabolized so rapidly in a whole organism that they would not be 
effective, and potential side effects such as nephro- or cardia-toxicity would not be 
detected until the compound is administered to a whole organism (33). 
An ideal chemotherapeutic agent would kill only cancer cells, and have little or no 
effect on normal cells. However, most chemotherapies cause severe side effects 
owing to the fact that they are not specific against cancer cells, and so normal cells 
die during the treatment as well. Thus there is an important distinction between 
cytotoxic compounds - that will kill all cells indiscriminately, and targeted therapies, 
that exploit some feature of the cancer cells to selectively kill only the cancer cells, 
The identification of differentially active compounds is hampered by the lack of 
normal control cell lines. Most normal human cells are extremely hard to culture, and 
only modification of normal cells (for example with telomerase or viral proteins) 
allows them to propagate in culture. However, the modifications made that allow the 
cells to divide in culture alter their behaviour from normal towards a cancerous 
phenotype. Thus matching a tumour type with a corresponding normal to determine 











1.4. Natural Products 
1.4.1. Introduction 
The source of compounds to be tested for activity in various screening programs 
varies. Many companies have large libraries of synthetic compounds for sale, and for 
the sake of sheer volume this can be a good option. However, chemical synthesis 
cannot match the complexity of natural products (representing the end point of 
millions of years of chemical evolution). Thus natural products (secondary 
metabolites) still remain an extremely promising reservoir of chemotherapeutic lead 
compounds, with over 60% of currently used chemotherapeutic agents derived or 
developed from natural sources (37;38). 
The diversity of chemical structures found in nature is the key reason behind the 
popularity, and effectiveness of natural products as chemotherapeutic agents. 
Millions of years of evolution have supplied chemical diversity that cannot be 
matched by combinatorial chemical libraries. 
1.4.2. Current natural product based anti-cancer agents 
The predominant source of natural products are plants and microorganisms. In the 
last 30 years, with the advent of better diving equipment, the potential of the marine 
environment as a source of natural products has begun to be tapped (39). 
Taxol or docetaxel is probably one of the most recognised chemotherapeutic agents 
from a natural source. In addition, the vinca alkaloids (most notably vincristine and 
vinblastine), isolated from the Madagascan rosy periwinkle (formerly Vinca rose us, 
now Catharanthus rose us) are another example of a plant-derived natural product 
used in cancer therapy. Their main mechanism of action is inhibition of microtubule 
assembly, causing tubulin to form self-aggregates (40). Other sources of natural 
products are microorganisms. The most well known examples from this group are 
probably the anthracyclines and bleomycins (41). 
Taxol, from the bark of the Pacific Yew tree has presented a model for the 
development of a natural product from identification, through drug trials and to the 
clinic (35). The development process of Taxol highlights many of the problems 











compound in extracts of the yew tree took several years. Following the successful 
identification of Taxol, supply became a problem. With an extremely complex 
structure, synthesis in the early years was close to impossible, and promised to be 
extremely expensive. Supply from the trees themselves was limited, as harvesting 
the bark in most cases destroyed the tree, and for the initial trials a great number of 
trees were destroyed for a small quantity of drug. However, a few years later it was 
found that a semi-synthetic analogue (docetaxel) had similar activity, and could be 
synthesized from the leaves of the yew tree, allowing sustainable harvesting (35). 
1.4.3. Marine natural products 
The marine environment is an extremely promising area for the identification of novel, 
biologically active compounds. More than 70% of the world's surface is covered by 
sea, and the biodiversity present in coastal waters is often many times higher than 
that found on land. One estimate is that the marine biodiversity more than equals that 
of Amazonian rain forests (41). This biodiversity is accompanied by an equal 
chemical diversity, and, to date, more than 14000 unique compounds have been 
identified from marine organisms (41). 
Many marine organisms (invertebrates, algae and micro-organisms) produce natural 
products as a chemical defence against predation or in a response to inter-species 
competition for limited resources (e.g. space on a reef or nutrients) (42). Interestingly, 
the isolation and identification of marine natural products by chemists, working in 
tandem with pharmacologists, over the last three decades has provided important 
lead compounds for the pharmaceutical industry, especially in the field of new anti-
cancer drug discovery (43-45). Marine biota are a unique reservoir of biomolecular 
diversity, not only because of the large number of species present in the oceans but 
also because the marine environment presents very different physiological and 
ecological challenges compared to those experienced by terrestrial species (46). As 
a consequence of the differences between terrestrial and marine habitats the initial 
expectation that marine organisms utilize unique biosynthetic pathways, or exploit 
variations on established biosynthetic pathways, to biosynthesize structurally unusual 
natural products has been validated by the complexity and novelty of the plethora of 











Blunt et al. 2006 have recently shown that sponges closely followed by micro-
organisms, coelenterates and tunicates (ascidians) are the primary source of 
bioactive metabolites in the marine environment. Interestingly, anti-cancer activity 
dominates the bioactivity reported for the secondary metabolites isolated from all four 
of these phyla and there are currently 21 sponge and tunicate metabolites in pre-
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Figure 1.7. Bioactive marine compounds. 
The activity of marine compounds identified in 2003 from various phyla. Activity includes 
antimicrobial (AM), antioxidant (AD), in vivo (IV) - including assays against brine shrimp and 
sea urchin eggs, anticancer (AC) including a range of assays including cytotoxicity, antimitotic, 
kinase and DNA binding assays, and other activity (Other) including antiviral, antifouling, 
feeding deterrant and ion channel assays. (Figure from Blunt et al. (47)) 
However, despite the promising results obtained in preliminary screens, very few 
marine compounds have reached the market, or even clinical trials, due to several 
problems. Chief among these is the issue of supply. The source organism may be 
extremely sparse, and yield of the active compound is often low (46;48). An obvious 
solution to this problem is mariculture, but many marine organisms grow slowly, and 











compound that would be needed for clinical trials and later commercialisation. 
Recent identification of symbiotic organisms as the source of several bioactive 
compounds offers the option of fermentation to produce active compounds. Many 
marine organisms are filter feeders, and thus concentrate large numbers of bacteria. 
Recent studies have shown a huge genetic diversity present in the sea especially 
the deep sea - this presents a potential source of new microorganisms that may in 
turn have huge numbers of unique compounds (49). However, identification of the 
source microorganisms, and optimization of culture conditions to produce the 
compound of interest present their own challenges. 
Despite these challenges, more compounds of marine origin are entering clinical 
trials, with a total of 44 marine compounds in clinical trials in 2004 (38). At present 
Ziconotide, a conotoxin identified from cone snail venom, is the only licenced marine 
compound (for the treatment of chronic pain), but many other compounds are in 
trials, with 13 new compounds entering trials in the last 6 years (2000 - 2005), all for 
cancer treatment (50), and 21 sponge and tunicate metabolites currently in pre-
clinical or clinical trials as potential anti-cancer treatments (46). 
Didemnin B was the first marine-sourced compound to enter clinical trials. It is a 
cyclic depsipeptide isolated from the tunicate Trididemnum solidum, and acts by 
inhibiting protein synthesis and introducing a cell cycle block in G1 phase. However, 
severe neuromuscular toxicity was observed, and trials were discontinued. More 
recently a related depsipeptide (aplidine) has been evaluated, and shows activity 
against a range of tumour types, and does not display as severe side effects (51). 
One of the most promisi g drug candidates from a marine organism is ET-743. This 
is a member of a class of compounds called ecteinascidins, all isolated from the 
tunicate Ecteinascidia turbinate. ET-743 has activity against most tumour cell lines in 
the nanomolar and sub-nanomolar ranges. Activity is related to its ability to 
selectively alkylate guanine residues in the minor groove, and also interact with DNA-
binding proteins, and this compound has been tested against a range of tumours (52-
54). 
Another highly promising group of marine compounds are the dolostatins. These are 
peptidic compounds which have cytotoxic activity. The most active of the group-
dolosatin 10 has entered clinical trials, but has failed to show significant activity, 











that may have higher activity in vivo, and two of these - soblidotin and synthadotin -
are also in clinical trials (50). 
Regardless of the source of their material, researchers developing novel 
chemotherapeutic agents to treat cancer have a particular interest in understanding 
the mechanism of action of their active agents. This understanding can facilitate the 
design of more effective agents, and the knowledge of a molecular target can assist 











1.5. General principles of chemotherapy 
Over the years anti-cancer agents have been classed into several major categories, 
based on their mechanism of action. These include tubulin interactive antimitotics, 
DNA damaging agents, antimetabolites, alkylating agents, topoisomerase inhibitors 
and DNA binders. 5-fluorouracil, discussed above, is a member of the antimetabolite 
class of anti-cancer agents. Discussed briefly below are the mechanisms of action of 
a few of these classes, with examples of these agents. 
1.5.1. Tubulin and actin inhibitors 
Tubulin and actin are the main cytoskeletal proteins in the cell, and both play 
important roles in cellular structure, motility and division. Tubulin plays a particularly 
important role in mitosis, forming the mitotic spindle along which the condensed 
chromosomes migrate to opposite sides of the cell prior to cell division (55). 
Both tubulin and actin are constantly remodeled. Both molecules form polymeric 
chains, that are continually restructured by the addition or removal of more tubulin or 
actin subunits. Molecules that inhibit either the polymerization, or the 
depolymerisation of tubulin generally cause cell cycle arrest in G2, at the 
metaphase/anaphase transition (40). 
The vinca alkaloids were one of the first classes of compounds found to interact with 
tubulin. Taxol was also discovered to inhibit tubulin dynamics, but stabilizes tubulin in 
the polymerized form rather than the depolymerised form. Other tubulin-interacting 
agents include colchicine, nocodazole, cryptophycins, estramustine. A more recently 
discovered compound is the marine natural product discodermolide (56). 
While the majority of antitumor molecules targeting the cytoskeleton interact with 
tubulin, actin also presents an attractive therapeutic target. Actin binding molecules 
include the cytochalasins, which were the first group of actin inhibiting compounds 
described. Many actin-inhibiting agents are being isolated from the marine 
environment, including the latrunculins (macrolides) (40), jasplakinolide (a 











1.5.2. DNA damaging agents 
DNA damage is an event that on first examination would not seem to be selective 
against cancer cells. However, damage to DNA can have far more serious effects on 
cancer cells than on normal cells due to changes in cellular processes such as DNA 
repair, increased cycling, and increased transcription. 
Many chemotherapeutic agents have been shown to interact with DNA, and there are 
many kinds of interactions that can cause cellular effects. Some agents simply bind 
to DNA, blocking the access of various proteins to DNA, thus preventing DNA 
transcription, unwinding by topoisomerases, and repair. Other agents directly modify 
DNA, causing mutations and damage. Types of alterations include alkylation, and 
crosslinking (59). 
The earliest DNA targeting molecules were also the earliest anti-cancer agents - in 
World War 2, an accident that involved exposure to nitrogen mustard gas in oil-based 
solution led to a large number of soldiers exposed to this mixture developing 
Iymphotoxic symptoms. This was later established to be due to the DNA alkylating 
activity of the nitrogen mustard gas, with the feature of targeting tissues with high 
proliferative indexes. This suggested a possible method of targeting rapidly dividing 
tumours, and was used to successfully treat lymphomas (59). 
Other DNA interacting agents include cisplatin (discussed in detail above), 
doxorubicin, mitomycin C and ET743. 
Some of the more recent agents targeting DNA are far more specific in their activity, 
and are a direct consequence of our increased understanding of DNA structure and 
function. The structure of DNA is far more complex than a simple double-stranded 
helix, and the secondary structures formed by DNA serve as highly selective targets 
for designed DNA interactive agents (60). 
1.5.3. Reactive oxygen species production 
Reactive oxygen species (ROS) are produced by a range of chemicals, exposure to 
radiation (UV etc.), as well as during normal cellular metabolism. ROS are a form of 
free radicals, and includes hydrogen peroxide, superoxide radical, hydroxyl radicals, 











reactive sulphur species. All free radicals include one or more unpaired electrons 
(61), and thus can react with biological molecules such as DNA, proteins and lipids. 
They can cause extensive damage to a cell, and cellular antioxidants such as 
superoxide dismutase (SOD) and catalase as well as the glutathione and thioredoxin 
systems exist specifically to deal with this stress. 
ROS production has been shown to be a factor in the activity of a variety of 
chemotherapeutic agents, including doxorubicin (62;63), fenretinide (64) and 
paclitaxel (65). ROS generation by chemotherapeutic agents is a good strategy since 
many tumours are already under increased oxidative stress, with many tumours 
having been shown to have both lower levels of antioxidant enzymes and increased 
levels of reactive oxygen species (66). Thus a slight increase in ROS, that will be 
tolerated by normal cells (with the exception of some tissues that are also under 
oxidative stress), will have far greater effects on cancer cells and may lead to cell 
death (67). 
ROS production by chemotherapeutic agents can also be the cause of side effects -
for example, the cardiotoxicity associated with doxorubicin has been linked to ROS 












1.6. Cell death 
The ultimate aim of any chemotherapy is to preferentially kill cancer cells. However, 
the consequences of cell death of a large number of cells in the body may be 
detrimental, especially if cell death is via the necrotic pathway. Necrotic cell death 
leads to inflammation and tissue injury, and thus the more desirable type of cell death 
for chemotherapeutic agents to cause is apoptosis. 
1.6.1. Apoptosis 
Apoptosis is also known as programmed cell death, reflecting the orderly chain of 
events that occurs leading to cell death. Apoptotis differs markedly to necrosis, where 
dying cells "explode", releasing cell contents into the surrounding environment. 
Apoptotic cell death neatly breaks down the constituents of the cell, and packages 
them into discreet apoptotic bodies, which are then phagocytosed (69;70). 
The process of apoptosis is carried out by a group of caspases (cysteine proteases), 
and is tightly controlled. Several pathways can be activated leading to apoptosis, but 
the two most well characterized are the death receptor mediated pathway and the 
mitochondrial pathway (Figure 1.8.). 
The death receptor mediated pathway is activated when a ligand for the death 
receptor binds. This then causes cleavage of caspase 8, which can then cleave (and 
activate) the effector caspase 3. An example of a death receptor ligand is TNFa 
(tumour necrosis factor a) which binds to the TNF receptor (TNFR) (71). 
A key event in the mitochondrial pathway is the permeabilisation of the mitochondrial 
membrane, triggered by an alteration in the levels of the pro and antiapoptotic BCL2 
molecules. This releases a number of proapoptotic factors into the cytoplasm 
including cytochrome c, which binds and alters the conformation of APAF1 (apoptotic 
protease activating factor 1). APAF1 binds and cleaves procaspase 9, and activated 
caspase 9 then activates caspase 3 (70). 
Both the death receptor pathway and the mitochondrial pathway ultimately result in 

















• Chrom bn oondensalon 
• Nuc r lragMfll8100n 
• CytoslclG 1 r JTDngOmonlC 
• .." lor 
• BH3-onty BCl·2 J)fole ~ o An1HlPOPC<M: BC ·2 proIelns O capa 
e (IAP) 
~ IPOP , • Pro poptobc OCt. 2 ptel na 0 
Figure 1.8. Apoptosis pathways. 
Apoptosis can occur following signalling from either the death receptors or the mitochondria, 
The mitochondrial pathway involves release from the mitochondria of cytochrome c, following a 
complex interplay of pro- and -anti-apoptotic stimuli. Cytochrome c then binds APAF1, which 
leads to the cleavage of procaspase-9 to caspase-9, which in turn activates caspase-3, 
The death-receptor pathway involves binding of a death receptor ligand to the death receptor, 
which leads to activation of caspase-S. This in turn leads to activation of caspase-3. 
Caspase-3 is an effector caspase which mediates many of the cellular events observed in 












Necrosis is a form of cell death where cells swell, and eventually lyse. Necrosis can 
be caused by a variety of stimuli including hypoxia, infection with microorganisms 
and immune responses. Necrosis plays an important role in preventing reproduction 
of pathogens, and recruiting an immune response (72). 
Evidence suggests that necrosis will also occur under conditions that would normally 
result in apoptosis if the cell has insufficient energy (ATP). Thus necrosis presents an 
alternative pathway to allow cell death. 
1.6.3. Autophagy 
Autophagy was originally described as a method of cell survival under starvation 
conditions, and is literally a process of cell autocannibalism, where autophagic 
vacuoles form in the cell to digest cellular components, releasing essential nutrients 
for cellular processes (70;73). As a starvation response, autophagy is only seen 
when cells are stressed, and thus there is great debate as to whether this is a 
survival pathway or a death pathway in mammalian cells. Theoretically, if nutrients 
are returned to cells undergoing autophagy, they should recover, but if starvation 
conditions continue, autophagy will eventually lead to death. Some evidence 












1.7. Project plan 
There is obviously a need for new chemotherapeutic agents to treat oesophageal 
cancer. In this project we attempted to identify novel compounds that might serve 
as new drug leads for the treatment of this disease. 
The objectives of this study were as follows : 
1. Establish a screening program, similar in approach to the NCI 60-cell line 
screen, using oesophageal cancer cell lines to identify compounds that may 
be of use as chemotherapeutic agents for oesophageal cancer. 
2. Screen marine extracts, and supply cytotoxicity data to assist with activity-
directed fractionation of active compounds. 
3. Identify novel compounds active against oesophageal cancer, and assess 












SCREENING OF MARINE SAMPLES FROM 
SOUTHERN AFRICAN WATERS 
2.1. Introduction 
As outlined in Chapter 1, the marine environment holds great promise as a source of 
novel natural products (secondary metabolites). In the southern African context the 
approximately 3000 km long coastline, stretching from Namibia in the west to 
southern Mozambique in the east, is inhabited by a rich diversity of natural product 
producing marine organisms (including invertebrates, algae, and marine 
microorganisms). This rich biodiversity stems from the three different biogeographical 
zones which characterize this stretch of coastline - the cool temperate west coast, 
the warm temperate southeast coast, and the subtropical east coast. (75). Each of 
these bio-geographical zones sustains distinct populations of marine flora and fauna 
and of the over 10 000 species of marine organisms recorded off the southern 
African coast, a large proportion (ca 12 %) are reported to be endemic to the region 
(75;76). Associated with high levels of marine invertebrate endemism are 
concomitant high levels of novel secondary metabolite chemical structural diversity 
which in turn suggests a high possibility of novel bioactivity (including biomedical 
potential) (77). The marine life of southern Africa and its associated natural product 
diversity therefore represents an as yet relatively untapped source of bioactive 
biomolecules. 
This potential was recognized over three decades ago in a South African government 
report, entitled 'Drugs from the Sea', which stated, "very little attention has yet been 
paid in South Africa to the recovery of drugs from the sea. This field offers exciting 
and rewarding challenges to South African scientists. Once research brings down the 
unit cost, the sea may offer a vast potential for the production of drugs for South 
Africa." (78). Prior to this report, research into marine chemistry in South Africa had 
been limited to marine phospholipids, long chain fatty acids and alcohols, and marine 
algal polysaccharides (79-81). 
In the 34 years since this report only limited South African research has been carried 
out to discover marine pharmaceuticals from South African organisms. However, 











Kashman (in collaboration with Mike Schleyer at Durban's Oceanographic Research 
Institute) and Mike Davies-Coleman (working with John Faulkner of Scripps Institute 
of Oceanography, and Pat Colin of the Coral Reef Research Foundation) have driven 
exploration of South Africa's marine chemistry and biodiversity (82). The work 
presented in this chapter explores the feasibility of screening South African marine 
organisms to identify compounds of potential use against oesophageal cancer. 
2.1.1. Marine compounds 
As part of our program to identify novel compounds with potential activity against 
oesophageal cancer, we established a collaboration with the Chemistry Department 
at Rhodes University. This gave us access to a wide variety of marine extracts and 
compounds, as well as the expertise of the chemists working to identify novel 
compounds from marine organisms. Samples obtained from Rhodes include crude 
extracts from marine organisms, fractions from various purification and separation 
procedures, and pure compounds. At all stages, fractionation, purification and 
chemical characterization were carried out by the chemists at Rhodes University. 
2.1.2. Overall strategy 
The flow chart in Figure 2.1. provides an overview of the overall screening strategy 
followed. Marine organisms were collected from a number of locations (Figure 2.4. 
and Figure 2.5.). In most cases collection was carried out by SCUBA, except at 
Marion Island where samples were collected by dredging. A portion of each organism 
was set aside for identification by marine biologists (Dr. Toufiek Samaai, CSIR, 
Durban, and Dr. Shirley Parker-Nance, Nelson Mandela Metropolitan University, Port 
Elizabeth), while a second portion was retained as a voucher specimen. A large 
portion of each sample was stored at -20°C for later use, while a small amount was 
extracted into methanol and then freeze-dried to yield a crude extract. These extracts 
were screened for activity against the oesophageal cancer cell line WHC01 as 
outlined in Materials and Methods, and active extracts identified in this way 
underwent an iterative bioassay guided fractionation process until pure compounds 
were obtained. At this stage the relative activity of the pure compounds was 
assessed by IC5D determination using the MTT assay. A group of related compounds 
were identified for further characterization and are discussed in Chapter 3. This 
chapter is based on the screening of marine extracts, bioassay-guided fractionation 











make the information more accessible to the reader, the results in this section have 
been presented in the context of the identity of the source organisms (identified by 
marine biologists) and the chemical fractionation and structural identification of the 
natural compounds (carried out by chemists at Rhodes University) . 
1. Sample collection 
2. Extraction 
! 




5. leso determination 
. __ ..... ,  Voucher specimen 
Portion stored at -20"C 
Portion used for identification 





6. Activity Assays 
(Chapter 3 and 4) 
Figure 2.1. Overall Strategy for screening, bio-assay guided fractionation and activity 
determination. 
All samples were processed in this manner. The sample was divided into 4 parts. The 
majority of each sample was stored at -20"C for later use if necessary. A voucher specimen 
and a portion for identification were retained by the marine biologists, while a final portion 
was extracted into methanol, to give a crude extract for screening. Extracts identified as 
active in our screening assay were fractionated, and each resulting fraction was tested for 
activity in the same screening assay, giving rise to an iterative bioassay guided fractionation 
process that eventually yielded pure compounds. The relative activity of these pure 
compounds was determined as an IC50 value derived from a dose response curve using MTT 
as an end point. A group of related compounds was identified for further study to determine 












To measure the activity of extracts and compounds in this study, we determined the 
toxicity of these samples against an oesophageal cancer cell line derived from a 
South African patient (83). This was carried out using an assay similar in format to 
that of the NCI 60 cell line screen (84). Initial screening was performed using the 
WHC01 oesophageal cancer cell line. This cell line was derived from a biopsy of an 
oesophageal squamous cell carcinoma from a South African patient (83), and has 
been shown to display characteristics typical of an oesophageal cancer (83;85-87), 
making it a useful first line screen. 
The 60 cell line screen conducted by the NCI was established in 1990, and performs 
high-throughput screening against a panel of 60 cancer cell lines using a 
sulforhodamine B assay to assess the survival of cells after exposure to 5 
concentrations of each test reagent (84). Researchers can submit compounds for 
testing by an online application, which is then assessed, and if sufficient evidence is 
supplied that the compound is novel, and may provide good results, the compound is 
tested. 
Due to the logistical considerations of using the NCI 60 cell line screen, it was thus 
convenient to set up a similar assay in our laboratory. This allowed us to modify the 
approach for our particular circumstances, to allow screening not only of compounds, 
but also of extracts, allowing activity-directed fractionation. (The NCI assay generally 
only accepts pure compounds of known structure for their screen.) The rapid 
turnaround of a local screen enables faster bioassay-guided fractionation, and costs 
(and logistical considerations) are reduced as samples do not need to be processed 
internationally. 
The NCI test each compound/extract at five concentrations, and assay for remaining 
cells using a sulforhodamine B assay which is a protein stain The initial assay in our 
study quantitates the cells surviving after treatment with 3 concentrations of each 
sample by staining with crystal violet (also a protein stain) (88). 
The NCI initially test compounds against a small range of cell lines, and then proceed 
to test compounds displaying activity against a panel of 60 cell lines. Our assay 
differs in the number and type of cell lines used. While the NCI is concerned with 











an initial panel of 3 cancer cell lines, and then the full panel of 60 cancer cell lines, 
we are interested in the predominant forms of cancer in South Africa. Currently our 
assay uses an oesophageal carcinoma cell line from a South African patient, which 
can easily be expanded to include a cervical cancer cell line. Since oesophageal 
cancer and cervical cancer are the main causes of cancer-related death among black 
South African males and females respectively, our program will hopefully provide a 
drug lead for these cancers. 
An advantage of using a limited number of cell lines in our screening system is the 
volume of material required. NCt guidelines for screening are for 1 0-15mg of pure 
compound, (though in the case of limited supply they will accept 5mg), However, we 
have routinely tested samples with masses of 1 mg or less. The small volumes 
required by our assay allows the chemists working on the project to retain a larger 
volume for further purification during activity-directed fractionation, which in turn 
increases the chances of identifying the active compound. 
The extracts from a wide variety of marine organisms were tested. These include 
sponges, ascidians, microorganisms and soft corals. The locations for the collection 
of these organisms varied from Marion Island, Algoa Bay, Tsitsikamma, Cape Town, 
Aliwal Shoal and Mozambique (Figure 2.4. and Figure 2.9.). 
2.1.4. Activity-directed fractionation 
Crude extracts found to be active in our screening program were selected for activity-
directed fractionation. These extracts are subjected to a variety of separation 
techniques which were all performed in the Chemistry Department at Rhodes 
University, and the resulting fractions then retested for activity in our assay. This 
process allows us to identify the active compound(s) in an extract through an iterative 
process between the collaborating laboratories at UCT and Rhodes University. 
2.1.5. ICso determination 
Once a pure active compound has been isolated, it is possible to more accurately 
quantitate the activity using the MTT assay to perform a dose response curve, and 
measure IC50 values. It is then possible to compare the activity of different 












An extremely desirable characteristic of a chemotherapeutic agent is differential 
activity, with high activity against cancer cells, and low activity against normal cells. 
The control cell line used during this study (to determine if any of the compounds 
tested displayed reduced activity against normal cells compared to tumour cells) was 
an epithelial cell line derived from a non-malignant breast tumour (MCF12A; ATCC# 
CRL 10783) (89). This is not the most appropriate control since it is neither 
oesophageal nor completely normal. However, as mentioned in Chapter 1, it is very 
difficult to maintain normal oesophageal epithelial cells in culture, and very few model 
systems are available. Consequently the results obtained from testing compounds 
against the MCF12A cell line may provide an initial indication of specificity. 
If a group of compounds is structurally related, comparing the activity of those 
compounds against one cell line may allow us to form a hypothesis regarding 
structure-activity relationships. We have made some conclusions of this nature with 
the group of quinone/hydroquinone structures discussed in Chapter 3, as well as 
several groups of compounds discussed below. These observations may help in the 
rational design of more effective chemotherapeutic agents. 
The activities of the marine natural products were compared to cisplatin, a commonly 
used chemotherapeutic agent for oesophageal cancer, that displayed an ICso of 13 











2.2. Results and Discussion 
2.2.1. Preliminary Screening 
A total of 479 samples were screened. Of these 175 were crude extracts, 278 were 
fractions from activity-directed fractionation steps, and 26 were pure compounds. 
Samples were tested against WHC01 cells at 3 different concentrations and the 
number of cells remaining after 48 hours of treatment was assessed using the crystal 
violet assay (88). All samples were resuspended at 30mg/ml (using mass/volume 
rather than molarity since most samples were extracts rather than pure compounds), 
then tested at final concentrations of 50, 10 and 1 IJg/ml with control (untreated wells) 
receiving equal quantities of solvent (DMSO). Plates were processed using crystal 
violet staining, which is a protein stain - the number of cells remaining after treatment 
stain blue, and when the stain is solubilised in acetic acid, the absorbance gives a 
reading proportional to the number of remaining cells. 
This method is not particularly accurate, and there are several shortcomings. False 
positives may occur, where a compound causes cells to detach, but does not cause 
cell death Since the protocol involves discarding culture medium, floating cells are 
discarded and an artificially low reading is obtained. In this case samples which do 
not cause cell death will test positive. False negatives may also occur, where a 
compound or extract precipitates and contributes to the absorbance reading, thus 
giving an artificially elevated reading, masking the true cytotoxicity of the sample. 
Both false negatives and positives are controlled for by observing cells prior to 
processing, and correlating the readings with the observations. 
Samples were scored according to the proportion of cells remaining at each 
concentration of treatment, compared to untreated. The scoring system ranked 
samples on a scale from 0 (no activity) to 3 (high activity), as illustrated in Figure. 2.2. 
and described in Materials and Methods. 
Of the 175 extracts tested, 54% (95/175) were inactive, 38% (67/175) had low to 
medium activity, and 7.4% (13/175) had high activity. Five of the active extracts were 
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Figure 2.2. Example of screening data against the human oesophageal cancer cell line 
WHC01. 
Sample A, with no activity would be scored 0, Sample B, which decreased the number of cells 
to below 10% of untreated at only the highest concentration tested, w uld be scored 1. Sample 
C reduced cell number to below 10% at the highest and medium concentrations, but not the 
lowest concentration, and would be scored 2, while sample D, which reduced cell number to 
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Figure 2.3. Activity scores for all extracts screened against WHC01. 
I 
Slightly over half of all extracts tested had no activity (Score = 0), one quarter had low activity 












The southern African coast spans three distinct biogeographical zones (Figure. 2.4.). 
The three regions are firstly the cool temperate West Coast north west of Cape Point 
(A), which is cooled by the Benguela current Upwellings of nutrient rich water along 
this coast result in high biomass, though less biodiversity amongst natural product 
producing marine invertebrates like sponges. Between Cape Point (A) and East 
London (D) is a warm temperate zone, in which the water temperature, although 
generally warmer than the West Coast, is cooler than the Coast The Agulhas 
Bank forms a wide continental shelf here, and the shallow, temperate waters hold 
great biodiversity in terms of marine invertebrates. North of East London (D) is the 
warm, sub-tropical coastal area, and north of Durban coral reefs (relatively 
common in warm tropical seas) are found. Both regions (D and E) support many non-
endemic circumtropical marine invertebrate species. 
The collections of marine invertebrates discussed in this thesis were made in the 
diverse, temperate zone (Tsitsikamma (B) and Algoa Bay (C), the tropical zone 
(Aliwal Shoal (F) and Mozambique (G» and Marion Island, a sub Antarctic island in 
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Figure 2.4. Biogeographical zones of the Southern African coastline, and collection sites. 
Thirteen samples were collected at Tsitsikamma (B), and 64 from Algoa Bay (C) , both of which lie 
in the warm temperate zone (from Cape Point (A) to East London (0)) . Thirty-nine samples were 
collected on the Aliwal Shoal (F), and 21 samples from Mozambique (G). (Image reproduced with 













The Tsitsikamma Marine Reserve and National Park is situated on the southern 
coast of South Africa in the diverse, temperate zone. As a protected area the marine 
life is relatively undisturbed. The collection took place in April 1995 and yielded a 
total of 13 extracts - 8 from sponges, 3 from ascidians and 2 from soft corals. The 
activity from these extracts was limited, with only 2 samples showing any activity at 
all, and that activity was the lowest category. The two samples with activity were 
isolated from a soft coral and a sponge. The low sample size from this location 
makes any statistical analysis of limited value, and it is difficult to draw any 
conclusion from these data. However, further collections at this location would be 
useful since the status of this area as a national park means that there are likely to 


































0~ .......... 1 .......... 1-......-___ 
• • • • o 1 2 3 
Activity 
Figure 2.5. Number of organisms (A), and activity of extracts (8) collected from 
Tsitsikamma National Park. 
A total of 13 samples were collected at Tsitsikamma National Park. Of these, 8 were sponges, 3 
ascidians, and 2 soft corals. The majority of these samples were inactive (11/13), and the 












2.2.1.1.2. Algoa Bay 
Algoa Bay is also located on the temperate south coast, and holds the harbour of 
Port Elizabeth. The collection at this location was carried out in July, 2004, and was a 
collection targeted to gather ascidian samples. Sixty-four extracts from this collection, 
all ascidian in origin, were tested . Of these samples the majority (79 .7%) were 
completely inactive, while 11 (17 .2%) had low activity, and only 2 (3.1 %) had 
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Figure 2.6. Number of organisms (A), and activity of extracts (B) collected from Algoa Bay. 
A total of 64 samples were collected at Algoa Bay. Since this was a directed collection, all 
samples were ascidians. The majority of these samples were inactive (52/64), 11 samples had 



















2.2.1.1.3. Aliwal Shoal 
The collection at the Aliwal Shoal was carried out in July 1994 and yielded 39 
extracts with the majority (32) from sponges, 6 from soft coral and 1 ascidian extract. 
The samples from this collection were the only samples other than those from Marion 
Island to give high activity, with 3/39 having high activity. All the extracts with high 
activity were derived from sponges. The ascidian extract was moderately active, and 
5 of the 6 soft coral extracts had some activity, though this was restricted to 3 with 
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Figure 2.7. Number of organisms (A), and activity of extracts (8) collected from the Aliwal 
Shoal. 
A total of 39 samples were collected from the Aliwal Shoal. This comprised of 32 sponge 
samples, 2 ascidian samples, and 6 soft coral samples . Approximately equal numbers of 
samples had no (score = 0) and low (score = 1) activity (13 and 15 samples respectively) , while 8 
samples had moderate activity (score = 2), and 3 samples had high activity (score = 3) . All the 

























Two collections were carried out in the Ponto do Ouro region of southern 
Mozambique in July, 1994 and October, 1995. Twenty-one extracts from this 
collection were tested with 15 sponge samples, 4 soft coral extracts and 2 ascidian 
extracts. None of the samples had high activity. Both ascidian samples were 
moderately active, while 2 of the soft coral samples were inactive and the other 2 
showed only low activity. About a third of the sponge extracts had no activity, another 
third had low activity, and the final third had moderate activity. 
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Figure 2.8. Number of organisms (A), and activity of extracts (8) collected from 
Mozambique. 
A total of 21 samples were collected from Mozambique. This comprised of 15 sponge samples, 2 
ascidian samples, and 4 soft coral samples. Approximately equal numbers of samples had no 
(score = 0), low (score = 1) and medium (score = 2) activity (7, 8 and 6 samples respectively), 











2.2.1.1.5. Marion Island 
Marion Island is a sub Antarctic island located about 1800 km south east of Port 
Elizabeth in the southern Ocean, and is the largest of the Prince Edward Islands 
group, The SA Agulhas - the Antarctic supply ship travels to the island to deliver 
supplies, as well as transporting scientists to and from the island at biannual 
intervals, and carries out various scientific experiments during the time it is based in 
the region around Marion Island. 
Two collections at Marion Island were carried out during April 2004 and April 2005, In 
contrast to collections at the other locations, where samples were collected by 
SCUBA, samples were collected by dredge from the SA Agulhas, Thirty-eight 
extracts from this collection were tested - 37 of which were sponge samples, while 1 
was an ascidian, The samples from Marion Island had the highest hit rate of any of 
the locations tested, with more than 25% of the samples (10/37) having activity levels 
of 3, almost 50% (19/37) of the extracts with activity of 2 or higher, and only 35% 
(13/37) with no activity, Owing to the way in which these samples were collected (by 
dredge, and without a marine taxonomist) it is suspected that many of the samples 
are actually duplicates of the same organism, This would have the effect of lowering 
the sample size, and at the same time would explain the high number of active 
extracts (most from the same organism) (91). Even so, the high percentage of activity 
observed in these samples means it would be imperative to perform another 
collection at this location and obtain a larger number of samples, with accurate 
identification and in quantities sufficient for activity-directed isolation and identification 













Figure 2.9. Collection areas around Marion Island. 
Samples in this collection were collected by dredge off the SAS Agulhas. Dredge locations 
and directions are indicated by the arrows numbered 1-13. (Image reproduced with 
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Figure 2.10. Number of organisms (A), and activity of extracts (8) collected from Marion 
Island. 
A total of 38 samples were collected from Marion Island. Unlike the other collections, these 
samples were collected by dredge, rather than SCUBA. The collection comprised of 37 sponges 
and 1 ascidian sample. 13 samples were inactive (score = 0), 5 samples had low activity (score 
= 1) and 9 samples had medium activity (score = 2) . This collection had the highest percentage 
of highly active samples, with 26% (10/38) of the samples showing high activity. The single 













Sponges are members of the Phylum Porifera in which three classes are recognized 
viz. Class Demospongia, Class Calcarea and Class Hexactinellida. Over 15000 
sponge species are known, the majority of which are marine (48;89) . Sponges are 
sessile, and rely on filter feeding for nutrition. Although sponges are the simplest 
multicellular organisms, they lack any true organs, and each cell can give rise to an 
entire organism. 
Sponges were the predominant organism from which extracts were obtained , with a 
total of 92 samples. Sponges yielded the most active extracts, with 13 extracts (14%) 
with high activity, 18 (20%) with moderate activity and 25 (26%) with low activity. This 
suggests that sponges represent an important source of bioactive metabolites, 
supporting observations made elsewhere (47). Faulkner has suggested that because 
marine natural product chemists generally require a taxonomic identification of the 
source organisms before they can publish their results in the chemistry literature their 
investigations are often biased towards groups of marine invertebrates which are 
taxonomically well-studied e.g. sponges (92) . 
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Figure 2.11. Activity of sponge extracts. 
A total of 92 extracts from sponges were tested . This group of extracts displayed the highest 
activity, with 14% (13/92) with a score of 3. 40% (36/92) of the samples had no activity (score = 












Ascidians belong to the Phylum Chordata, Subphylum Tunicata , Class Ascidacea 
and are commonly referred to as tunicates. Tunicates are filter feeders, siphoning 
water through one opening and out another. Although they may exist as single 
organisms, many species are colonial and over 2500 species of ascidians are known. 
Ascidians were the second most common source organism for our studies, with 71 
ascidian extracts tested for activity. Extracts derived from ascidians had the lowest 
levels of activity with only 5 (7%) with moderate activity and 11 (14%) with low 
activity. None of the extracts isolated from ascidians displayed high activity. Since 
ascidians were the third most common source of bioactive compounds (47) , we were 
surprised by the low activity observed in these samples . However, since the majority 
of these samples were collected at one location, this may reflect a site-specific lack 
of activity. It is also possible that bioactive compounds exist in these samples, but at 
such low concentrations that their activity was not detectable in our assay. 
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Figure 2.12. Activity of ascidian extracts. 
A total of 71 extracts from ascidians were tested . No extracts had high activity (score = 3) . More 
than % of the samples had no activity (55/71), 15% (11/71) had low activity (score = 1) and only 











2.2.1.2.3. Soft Corals 
Soft corals (also known as octocorals) belong to Phylum Cnidaria, Class Anthozoa, 
Order Alcyonaria . They are colonial organisms made up of multiple polyps, each with 
eightfold symmetry. 
There were only a very limited number of soft coral extracts - 12 in total. None of 
these had high activity, but 2 extracts (17%) had moderate activity, 6 extracts (50%) 
had low activity and 4 extracts (33%) had no activity. This indicates that there may be 
interesting active metabolites in soft corals and these organisms may be worthy of 
further investigation at a later point. 
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Only a very limited number of soft coral samples were collected and tested. Of the 12 samples, 
none had high activity (score = 3). However only 4 of the samples had no activity (score = 0), half 











2.2.2. Bioassay guided fractionation 
16 pure compounds were identified from 5 active extracts via activity-directed 
fractionation. Several other compounds were isolated based on interesting chemical 
properties prior to this project. In the discussion below the compounds isolated via 
activity directed fractionation are discussed under the source organism. In some 












2.2.2.1. Leptogorgia gilchristii 
The gorgonian Leptogorgia gilehristii is an octocoral (sea fan or gorgonian) that was 
collected in Mozambique off Ponto Malongan. The moderately active meU,anolic 
extract was considered a good candidate for bioassay guided fractionation due to its 
large volume and the interesting NMR spectra obtained. 
2.2.2.1.1. Bioassay guided fractionation 
Fractionation involved non silica-based chromatography (Polymeric reversed-phase 
separation - HP-20 column), followed by normal-phase flash- and HPLC using diol 
solid supports. This resulted in the isolation of 3 pure compounds, malonganenones 
A, 8 and C (Figure 2.14.) (93). 
2.2.2.1.2. IC50 determination 
The malonganenones are tetraprenylated alkaloids. Many polyprenylated quinone 
and purine metabolites have been previously isolated from southern African 
octocorals. Our collaborators have previously isolated the triprenyl hydroquinone 
rietone (Figure 2.14.) from the soft coral A/cyonium faud (94), as well as a series of 
triprenylated quinones and hydroquinones from the Arminacean nudibranch Leminda 
mll/eera (95) (Figure 3.1.). These are quite likely to be octocoral in origin as the 
nudibranch feeds on various octocorals (96). The series of triprenylated 
hydroquinones and quinones from Leminda mil/eera are discussed in detail in 
Chapter 3, and so this section focuses on the activity observed for the 
malonganenones and rietone. 
Malonganenones A, 8 and C are interesting from a biochemical perspective since 
examples of purine, rearranged purine and formamide secondary metabolites from 
octocorals are rare. Malonganenone A is the first 3,7 -disubstituted hypoxanthine from 
a marine source, and malonganenones 8 and C are the first formamide structures 
isolated from gorgonians (93). The bioactivity of the malonganenones was assessed 

















Figure 2.14. Structures ofthe compounds identified from Leptogorgia gilchristii by activity 
directed fractionation. 
Also shown is the structure of a related compound, rietone, identified in a previous project from 
the soft coral A/cyanium fauri (94). 
The malonganenones and rietone were assayed against a number of cell lines, 
following initial fairly positive results in our primary screen against WHC01, with 
activity (IC50) varying from 17 !-1M to 57 I-lM. The cell lines tested were 6 oesophageal 
cell lines of either South African (WHCO) or Japanese (KYSE) origin, and one control 











The activity among the malonganenones against the different cell lines was fairly 
consistent, with the closed ring structure of malonganenone A conferring similar 
activity than the open ring structure of malonganenone B in all cell lines. Together 
these two compounds (malonganenone A and malonganenone 8) appeared more 
active than the acyclic formamide (malonganenone G). The only exception to this 
case was the decreased activity of malonganenone B observed against WHG05. 
The activity of rietone was similar to that of malonganenone G in most of the cell 
lines. 
ICso values in JlM (95% CI) 
Malonganenone A Malonganenone B Malonganenone C Rietone 
16.6 14.6 57.7 54.0 WHC01 
(11.0-25.2) (10.9-19.6) (52,9-63.0) (46.0-63.5) 
4.9 2.2 27.9 32.2 
WHC05 
(2.4-10.0) (1.4-3.3) ( 18,0-43,2) (23.4-44.4) 
51.2 26.8 77,5 
> 100* WHC06 
(46.2-56.7) (19.5-36.6) (66,9-89,7) 
KYSE70 
25.9 33.4 
> 100* > 100* 
(16,5-40.7) (25.8-43.3) 
14.5 11.6 19.4 
> 100* KYSE180 
(8.6-24.3) (7,3-18.2) (13.6-27.6) 
16.4 12.8 > 100* > 100* KYSE520 
(9.2-29.2) (7.6-21,7) 
13.0 13.0 15.3 7.4 
MCF12A 
(6.1-27.5) (7.0-24.0) (8.8-26.7) (6,2-8.9) 
Table 2.1. Anti-oesophageal cancer activity ofthe malonganenones and rietone . . 
The IG50 values (and 95% confidence intervals) obtained for the malonganenones and rietone 
against 6 oesophageal cancer cell lines, and the non-malignant breast epithelial cell line MGF12, 











Malonganenones A and B displayed similar activity against the normal cell line 
(MCF12A) as against the oesophageal cancer cell lines. However rietone was 
surprisingly 4-6 fold more active against MCF12A than against the oesophageal 
cancer cell lines. This was observed in 2 independent ICso determinations, and may 
reflect the routine alteration of pathways associated with tumorigenesis conferring 
resistance against rietone. 
Rietone was previously assayed for its anti-HIV properties in the NCI in vitro anti-HIV 
bioassay, but the activity displayed was inadequate to prompt further work (ICso = 
9.32 fJM) (94) Our results suggest a potential use for this compound as an anti-
cancer agent, but further testing against a wider range of tumours is recommended in 
light of the increased toxicity of this agent against the control cell line. 
Malonganenone C showed increased toxicity against the normal cell line MCF12A 
when compared to the oesophageal cancer cells (with the excepti n of KYSE520). 
This observation should be confirmed by testing this compound on a broader panel of 











2.2.2.2. Strongylodesma aliwaliensis 
The Latrunculid sponge Strongylodesma aliwaliensis (Family Latrunculidae) was first 
identified by our collaborators in 2004 (97). (Figure 2.1S.A) 
2.2.2.2.1. Bioassay guided fractionation 
The aqueous MeOH partition of the sponge Strongylodesma aliwaliensis was found 
to possess high activity (score::: 3) in our assay. A portion of this extract was 
dissolved in MeOH and was fractionated using a variety of techniques including HP-
20, Ci8 Sep-Pak (columns) C18-RP-HPLC to give the known compounds damirone 
C, makaluvamines I and M (98), and four novel compounds N-1-P-D-
ribofuranosyldamirone C and N-1-p-D-ribofuranosylmakaluvamine I (99), makaluvic 
acid C and N-1-[3-D-ribofuranosylmakaluvic acid C (100). The structures of all these 
compounds are shown in Figure 2.15.B. 
2.2.2.2.2. ICso determination 
The low yield of makaluvamine I isolated from the extract precluded activity 
determination. All the other compounds isolated from S. aliwaliensis were evaluated 
for anti-oesophageal cancer activity, and were evaluated against 3 oesophageal 
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Figure 2.15. Strongylodesma aliwaliensis (A), and the compounds identified from this 
sponge by activity diirected fractionation (8). 
Strongylodesma aliwaliensis is a green, ball shaped sponge. In this picture, it is covered in 











IC50 values in jJM (95% CI) 
WHC01 WHCOG KYSE30 
Damirone C 
55.7 78.3 77.9 
(51.2-60.5) (69.8-87.9) (72.7-83.4) 
Makaluvamine M 
0.19 6.8 3.2 
(0.17-0.21) (3.0-13.2) (2.7-3.9) 
N-1-(3-D-ribofuranosyl damirone C 
37.9 75.7 71.6 
(32.9-43.7) (68.5-83.6) (59.0-87.0) 
N-1-(3-D-ribofuranosyl makaluvamine I 
1.45 5.6 3.2 
(1.44-1.46) (4.2-7.4) (2.8-3.7) 
Makaluvic acid C >150* >150* >150* 




Table 2.2. Anti-oesophageal cancer activity of the compounds isolated from the 
sponge Strongylodesma aliwaliensis. 
These compounds were tested against three oesophageal cancer cell lines. 











The ICso values suggest that the addition of the sugar moiety improves activity 
slightly (comparing N-1-I3-D-ribofuranosyldamirone C to damirone C, and N-1-I3-D-
ribofuranosylmakaluvic acid C to makaluvic acid C). The alteration of the 
pyrroloiminoquinone nucleus in N-1-I3-D-ribofuranosylmakaluvamine I to the ortho 
quinone structure in N-1-I3-D-ribofuranosyldamirone C results in a significant loss of 
activity, confirming the important role played by the pyrroloiminoquinone mOiety in 
determining the anticancer activity of these compounds (101). 
Interestingly, we had also had access to two compounds with similar structures 
isolated by our collaborators in a previous project. These were tsitsikammamine B 
and discorhabdin A (Figure 2.16.). 
Tsitsikammamine B was isolated with tsitsikammamine A and two novel 
pyrroloiminoquinone alkaloids (14-bromodiscorhabdin C and 14-
bromodihydrodiscorhabdin C) from Tsitsikamma favus from the Tsitsikamma Marine 
Reserve (1 02). 
Tsitsikammamine B Discorhabdin A 
Figure 2.16. Tsitsikammamine Band discorhabdin A. 
These compounds are similar to those isolated from Strongylodesma aliwaliensis, and this 











Discorhabdins are found predominantly in the genera Latrul1culia, while 
makaluvamines are generally isolated from the genera Zyzzya (99). The source 
sponge for tsitsikammamine B was found to share morphological characteristics 
between these two genera, and this resemblance was expected to extend to the 
secondary metabolites isolated from it This was the case, with the compounds 
isolated having similarity to both the discorhabdins and the makaluvamines (102). A 
number of the discorhabdins have been shown to have potent antitumour activity 
(103-105), while tsitsikammamine B has been shown to intercalate into DNA and 
cause cleavage by inhibiting topoisomerase I (103). Our results show similar levels of 
activity of discorhabdin A and tsitsikammamine B against an oesophageal cancer cell 
line, and a cervical cell line (Table 2.3.) to that seen in a previous study (103), where 
discorhabdin A showed an IGso of 0.007 f,lM, and tsitsikammamine Ban IG50 of 2.38 
IJM against the HGT116 cell line. 
ICso values in J.lM (95% CI) 
WHC01 ME180 MCF12A 
Tsitsikammamine B 1.3 IJM 1.0 f,lM 0.9 IJM 
(0.9-1.8) (0.8-1.1) (0.9-1.0) 
Discorhabdin A 6.3 nM 13.7 nM 9.0* 
(1.1-34.9) (12.4-15.2) 
Table 2,3. Anti-oesophageal cancer activity of tsitsikammamine Band discorhabdin A 
against several cell lines. 
These compounds were tested against the oesophageal cancer cell line WHC01, the 
cervical cancer cell line ME 180 and the non-malignant breast epithelial cell line MGF12A. 











2.2.2.3. Axinella weltneri 
The sponge Axinella weltneri was collected by SCUBA from a reef off Ponto do Oura 
in southern Mozambique in July 1994 (Figure 2.17.A). 
2.2.2.3.1. Bioassay guided fractionation 
The EtOAc partitioned fraction from the sponge Axinella weltneri had moderate 
activity in our assay, and was fractionated on a silica gel column. The most active of 
these fractions was subjected to semi-preparative HPLC purification. One of the 
resulting fractions exhibited significant activity against WHC01 and was determined 
by NMR to be the triterpene sodwanone A (Figure 2.17.B.). 
2.2.2.3.2. ICso determination 
Sodwanone has previously been identified fram Axinella weltneri (106), and its 
anticancer activity against a lung carcinoma cell line reported (107). However, its 
identification by activity-directed fractionation in this project validates the potential of 
our system to identify compounds of interest. 
In addition, sodwanone A displayed substantial activity (IC5o of 1.2 - 1.7 f,lM) (Table 
2.4.) against 3 oesophageal cancer cell lines, which compares favourably to the 
results reported for the lung carcinoma cell line mentioned above (IC5o = 12 f,lM) 
(107). 
Current work by our collaborators has focused on producing synthetic analogues of 
sodwanone A, and two analogues have been tested to date. Unfortunately both of 














Figure 2.17. Axinel/a weltneri (A), and sodwanone A (B), isolated by an activity-directed 
fractionation process. 











2.2.2.4. Aplysil/a sulphurea 
The sponge Apfysil/a sufphurea was also collected by SCUBA from a reef at Ponto 
do Ouro in southern Mozambique in July, 1994. 
2.2.2.4.1. Bioassay guided fractionation 
Four compounds were isolated from the EtOAc extract of the sponge Aplysil/a 
sulphurea collected in Mozambique, which exhibited moderate anti-oesophageal 
cancer activity (score = 2) in our screening system. Fractionation on an HP-20 
column led to the isolation of (+)-curcudiol, reported concurrently from the sponge 
Didiscus flavus (108) and from Epipolasis sp,(1 09). The known compound 
aplysulphurin, a common metabolite of the spong ian diterpene class originally 
isolated from an Australian collection of A sulphurea (110) was eventually purified by 
crystallization. The supernatant mother liquor from the recrystallization was 
chromatographed using first silica gel and then silica HPLC to yield 9,11-
dihydrogracilin A which was originally isolated from the Antarctic sponge Dendrilla 
membranosa (111). An inactive peroxy-steroid was also isolated and identified from 
an active fraction. The structures of all these compounds are shown in Figure 2.18. 
-OH 
Aplysulphurin 9,11-dihydrogracillin peroxy-steroid (R=?) 












2.2.2.4.2. IC50 determination 
Both of the diterpenes (aplysulphurin and 9, 11-dihydrogracillin) displayed high 
activity against all three cell lines tested. This activity was greater than that of 
cisplatin against the oesophageal cancer cell line WHC01 (IC5o = 13 I-lM). Curcudiol 
had very low activity in our system, with slight activity against WHC01, and no 
activity against the other cell lines, and the peroxysteroid was completely inactive 
(Table 2.4.). 
ICso values in IJM (95% CI) 
WHC01 WHC06 KYSE30 
Sodwanone A 
1.3 1.7 1.4 






3.5 10.0 7.0 
(1.7-7.0) (7.7-13.1 ) (4.7-10.5) 
9, 11-Dihydrogracillin A 
1.1 1.0 1.5 
(0.7-1.8) (0.7-1.4) (1.3-1.6) 
Table 2.4. Anti-oesophageal cancer activity of sodwanone A, and the compounds 
isolated by activity-directed fractionation from A. sulphurea. 
The ICso values for these compounds was determined against three oesophageal cancer cell 











2.2.3. Lyngbya majuscula (Homodolastatin 16) 
Homodolastatin 16 is a cyclic depsipeptide that was isolated from a Kenyan 
collection of the cyanobacterium Lyngbya majuscula (112). This compound was 
isolated prior to the start of the collaboration as part of an NMR (Nuclear Magnetic 
Resonance) based targeted search for bioactive depsipeptides from East African 
marine cyanobacteria. This compound was submitted for screening because of the 
well-documented anti-cancer activity of dolastatin 16 (112). Homodolastatin 16 is a 
higher homologue of dolastatin 16 and differs from the latter compound by 
possessing an extra methylene group. 
Dolostatin 16 
Figure 2.19. Dolostatin 16 and homodolostatin 16. 




Homodolostatin 16 was isolated from the cyanobacterium Lyngbya majuscu/a. It differs from 
dolostatin 16 by the presence of an additional methyl group. 
The dolastatins are a group of depsipeptides with similarity to the original member of 
this group, dolastatin 10. Dolastatin 10 was originally isolated from the sea hare 
Do/abella auricularia by Pettit et al. in the 1970's, but owing to exceptionally low yield, 
the active portion of the highly active extracts was only identified almost 15 years 
later (113). Dolastatin 10 has high antiproliferative activity (ED5o of 4.6x1 0-5 IJg/ml 
against murine PS leukemia cells), and was found to bind to tubulin, strongly 
affecting microtubule assembly (114). Dolastatin 10 has been tested in Phase I and II 
trials, but trials were discontinued as it exhibited peripheral neuropathy in 40% of 
patients, and was not effective in patients with hormone-refractory metastatic 
adenocarcinoma and recurrent platinum sensitive ovarian carcinoma. However, it has 











Dolastatin 16, was originally isolated from the same sea hare, Do/abella auricularia, 
and later from a Madagascan collection of L. majuscula. It has been reported to be 
cytotoxic against a variety of cancer cell lines, including lung (NCI-H460 : GI 50 
0.00096 IJg/ml), colon (KM20L2 : GI 50 0.0012 IJg/ml), brain (SF-295 : GI 50 0.0052 
IJg/ml) and melanoma (SK-MEL5 : GI 50 0.0033 IJg/ml) (G150 - concentration resulting 
in a 50% inhibition of growth) (112). We thus tested homodolastatin 16 against two 
oesophageal cancer cell lines (WHC01 and WHC06), as well as the cervical cancer 
cell line ME180. While there was significant activity against these cell lines (WHC01 : 
IC50 4.3 IJg/ml, WHC06 : ICso 10.1, ME180 : ICso 8.3 IJg/ml), the activity observed 
was substantially lower than that reported for dolastatin 16 (112). In this case I have 
converted the IC50 values of homodolastatin from IJM to I-lg/ml to facilitate the 
comparison between our results and that of Pettit et a/. Regrettably no dolastatin 16 












In the course of this project, a cheap, relatively rapid screening program was 
established. Currently the cell line utilized for this screen is the oesophageal cancer 
cell line WHC01, but this could be expanded to include other cell lines of interest. 
Oesophageal and cervical cancer are the 2 most common causes of cancer related 
death among men and women in southern Africa respectively. Thus identifying 
agents that may be used as chemotherapeutic agents for these cancers is an 
extremely important objective. 
This screening program can be used to test samples from any source, but during the 
course of this project we have focused on screening marine natural products. A total 
of 479 samples were processed. These included 175 extracts from marine 
organisms, After identifying a number of extracts as good candidates, we proceeded 
with activity-directed fractionation, testing a total of 278 fractions, of the extracts of 
interest. These gave rise to a number of compounds. In addition several compounds 
identified in earlier projects were also tested. 
In the course of screening, a large number of primary extracts were tested, Since we 
know the source organisms of these extracts, we are able to draw some conclusions 
regarding the most likely organisms to yield active compounds. According to Blunt et 
al. (2006) sponges are the primary source of bioactive metabolites in the marine 
environment, closely followed by micro-organisms, coelenterates and tunicates 
(ascidians) (46). Our results support this observation with the highest activity 
samples being derived from sponges, The few soft coral samples tested were on 
average more active than the ascidian samples, but our numbers are too low to draw 
a conclusion from this. 
The compounds identified by bioassay-guided fractionation show the potential of our 
screening program and close collaboration between chemists, biochemists and 
taxonomists to yield bioactive compounds from southern African marine sources, 
Identification of the known compound sodwanone A by activity-guided fractionation 
shows the potential of our system to identify viable drug leads, and the number of 
unique, cytotoxic compounds identified from a relatively small number of organisms 
and fractions, at minimal cost shows the viability of a screening program of this sort 












CYTOTOXIC EFFECT OF KLMs ON OESOPHAGEAL 
CANCER CELLS 
3.1. Introduction 
In our search for novel cancer therapies from the marine environment, we identified a 
group of related compounds with activity against our screening cell line. These 
compounds had been identified prior to our collaboration by chemical methods in an 
investigation of the sequestered chemistry of the Arminacean nudibranch Leminda 
mil/eera. This investigation yielded a variety of novel chemical structures as well as 
the previously identified millecrones A and B, isofuranodiene and (+)-8-
hydroxycalamenene (96). The novel compounds identified included a group of 
related triprenylquinones and triprenylhydroquinones (95). 
3.1.1. Source and isolation of compounds 
Leminda mil/eera (Griffiths, 1985) (Figure 3.1.) 
is an Arminacean nudibranch, a marine 
gastropod that lacks a shell (hence nudi -
naked, branch - gills). Nudibranchs are 
members of the Phylum Mollusca, Class 
Gastropoda, Subclass Opisthobranehia, 
Order Nudibranchia, Suborder Arminina. L. 
mil/eera is the only member of the Lemindidae 
family of nudibranchs, and is endemic to the 
South African coastline, occurring between 
the Cape Peninsula and Kwazulu Natal. This 
nudibraneh has previously been shown to 
feed on octocorals, and both octocoral 
spicules and metabolites were identified in 
samples of L. mil/eera from the Transkei coast 
(96) . 
Figure 3.1. The Arminacean nudibranch 
Leminda millecra. 












An abundance of L. mil/eera in the waters of Algoa Bay provided a source for further 
elucidation of the sequestered chemistry of this organism (95), and the subsequent 
biological assays described in this thesis. Two collections of L. millecra (a total of 
specimens collected in Algoa Bay in October 1998 and February 1999) were 
processed through a series of purification steps, including silica gel chromatography 
and HPLC to yield the hydroquinones and quinones discussed in this chapter (Figure 
3.2.). The reader is referred to McPhail ef at. (95) where a more detailed description 
of the isolation and characterization of these compounds is provided. 
Previously, similar structures have been isolated from the marine fungus Penicillium 













Figure 3.2. Triprenylquinones and hydroquinones isolated from the Arminacean nudibrach 
L millecra. 
The nomenclature is that originally used by the chemist isolating these compounds, and has been 











3.1.2. Quinones as chemotherapeutic agents 
Many biologically active quinones exist, and are in use as therapies for a variety of 
diseases, and are widely used in the treatment of malignancies. The quinoid 
anthracycline antibiotics are amongst the most utilized anticancer agents ever 
developed (68; 117). Quinones in clinical use include doxorubicin, streptonigrin, 
mitomycin c and diaziquone, while E09 and the aziridinylbenzoquinones DZQ 
(diaziridinylbenzylquinone) and RH1 are currently in clinical trials (118) (Figure 3.3.). 
Despite the fact that over a thousand quinone compounds have been tested for 
anticancer activity, and the widespread use of many quinones as anticancer agents, 
the mechanism of action of these compounds, and the contribution of the quinone 
structure to the activity of these compounds remains uncertain. This is due to the fact 
that antitumour quinones generally consist not only of a quinone moiety, but also 
other structures that may contribute to toxicity (117). General mechanisms that have 
been described for quinone reactivity include quinone redox cycling and conjugation 











Diaziridinylbenzoquinone (DZQ) R1 "" R2 ::: H 
RH1 R1 ::: CH 3 • R2 CH20H 
Figure 3.3. Quinones of clinical significance. 
Mitomycin C, doxorubicin and streptonigrin are agents in clinical use, while E09 and the 











3.1.3. Experimental approach 
The compounds isolated from L. mille era were evaluated for activity against the 
oesophageal cancer cell line WHC01 as a model system, and once activity was 
identified, the activity of the most abundant (and most active) compounds was tested 
against a wider panel of cell lines. We then determined the involvement of apoptosis, 
necrosis and cell cycle perturbations in the cellular response to treatment with these 
agents. 
In Chapter 4, the mode of action of these compounds is explored. 
Unfortunately, one of the major problems associated with compounds extracted from 
marine organisms is a scarcity of supply. There was a limited amount of each of the 
KLM compounds available, and thus it was necessary to limit mechanistic studies to 
only one, and in some cases two of the most abundant (and most active) 
compounds. In some cases, the activity of the entire group of compounds was 












3.2.1. Effect of KLMs on cell viability 
Initial screening of compounds KLM 153 - KLM 159 on the viability of WHCO 1 cells 
was performed using the crystal violet assay (Figure 3.4.) . All these compounds 
caused almost complete cell death at the highest concentration tested (50 j.Jg/ml). 
Most (except KLM157) reduced the cell number to less than 50% of untreated at 10 
j.Jg/ml. At 1 j.Jg/ml, most of the compounds increased the cell number slightly. The 
only exception to this was KLM153. Cell numbers increased significantly in the case 
of several compounds - e.g. KLM154 and KLM159 which increased cell number to 
almost 150%. This increase was confirmed by visual observation of the cells prior to 
processing for screening, and was not associated with any form of precipitate. 
Figure 3.4. Effect of the KLMs on cell viability in our initial screening assay. 
Initial screening of these compounds was carried out as outlined in Materials and Methods. 
Compounds were diluted and added to wells in duplicate at three concentrations, and following 
a 48 hour incubation, the plate was processed using the crystal violet stain. Values are 
expressed as the % of untreated cells (as measured by absorbance at 595nm). Error bars 











3.2.2. ICso determination 
Following the promising results of the initial screening assay, these compounds were 
evaluated for their cytotoxic activity using the MTT assay to determine IC50 values 
against the oesophageal cancer cell line WHC01. 
The compounds showed varying activity against these cells (Table 3.1.), and their 
close structural similarity allowed us to make some tentative structure/activity 
observations. Changes in the substitution pattern at the 1 and 4 positions yield 
varying activity, with the most active compounds being those with a non-esterified 
hydroquinone nucleus (e.g. KLM155 and KLM156). The quinone nucleus of KLM153 
and KLM154 is the least active of the three variants, while the acetyl substitution of 
KLM157 is less active than the hydroquinones, but more active than the quinones 
(Figure 3.5.). Changes in the geometry of the double bonds in the side chain also 
affect activity - KLM153 and KLM155 (all trans) are more active than KLM154 and 
KLM156 (trans,cis) (Figure 3.6.). KLM159 (which differs from KLM155 only in the 
substitution of a hydroxyl group for a carbonyl group on the triprenyl side chain) is 
less active than KLM155. There were insufficient quantities of KLM158 to repeat the 
IC50 determination for this compound. 
Compound ICso [IJM] CI (95%) 
KLM153 37.9 37.7 - 38.0 
KLM154 83.3 82.1 - 84.5 
KLM155 9.4 9.4 - 9.5 
KLM156 12.9 12.5-13.3 
KLM157 42.6 42.6 - 42.7 
KLM158 19.4* 
KLM159 32.7 32.5 - 33.0 
Table 3.1. ICso values (and 95% confidence interval) for KLM's against the oesophageal 
cancer cell line WHC01. 
Dose response curves for each KLM were performed against the oesophageal cancer cell line 
WHC01 as outlined in Materials and Methods. Each experiment was performed in quadruplicate 















IG50 = 19.39 
> KLM153 
KLM154 
IG50 :::: 83.32 
IG50 = 9.45 IG50 = 37.8 
Figure 3.5. Changes in activity based on the substitution of the ring 
KLM155 
IGso :::: 9.45 
KLM153 
IGso :::: 37.8 
> 
KLM156 
IGso :::: 12.88 
KLM154 
IGso 83.32 











The triprenyl hydroquinone rietone discussed in Chapter 2 (Section 2.2.2.1), was 
isolated from the soft coral A/cyonium taur; (94), and has moderate activity against 
the oesophageal cancer cell lines tested, with activity in a similar range to that of 
KLM157 against WHC01 (Table 2.1). 
The most active compound (KLM155) was evaluated against a range of cell lines, 
including oesophageal cancer cell lines WHC01 and 6, cervical cancer cell lines 
ME180 and SiHa and the benign breast epithelial line MCF12A, as a control (Table 
32.). KLM155 displayed cytotoxicity against most of the cell lines tested, with the 
exception of the cervical cancer cell line SiHa, which was resistant up to the highest 
concentration of KLM155 tested (150 IJM). 
Cell line IC50 [IJM] CI (95%) 
WHC01 9.4 9.4 - 9.5 
WHC06 5.8 5.6 6.0 
MCFi2A 31.9 31.6 - 32.3 
MEi80 33.9 33.7 - 34.1 
SiHa >150 
Table 3.2. ICso values (and 95% confidence interval) for KLM155 against a variety of cell 
lines. 
Dose response curves for KLIVI155 were performed against WHC01 and WHC06 (oesophageal 
cancer cell lines), MEi80 and SiHa (cervical cancer cell lines) and MCF12A, a benign breast 











3.2.3. The effect of KLM155 on cell growth and survival 
A growth curve of cells with and without various concentrations of KLM155 was 
carried out to determine whether the reduction in cell number was due to a cytotoxic 
or cytostatic effect (Figure 3.7.). A low number of cells (1500/well) was seeded in 
quadruplicate in 96 well plates (with replicate plates for each time point), and allowed 
to settle overnight before various concentrations of KLM155 were added. MTT was 
added to replicate plates at each time point and the OD595nm measured as a 
surrogate of cell number. 
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Figure 3.7. Growth curve of WHC01 cells reated with varying concentrations of KLM155. 
Cells were plated at 1500 cells per well and allowed to settle overnight. They were then treated 
with varying concentrations of KLM155 and MTT reagent was added at the relevant time points. 
Each point represents the mean of 4 wells, with standard deviation, and this is representative of 
at least two independent experiments. 
At the lowest concentration tested (5 IJM), very little effect on WHC01 cell growth 
was observed, though cell number was slightly higher than untreated cells at 12 and 
24 hours. This may be a correlation with the increase in cell number seen at low 
concentration in the initial screening experiments (Figure 3.4.). At the higher 
concentrations tested (10 IJM and 20 !-1M), cell number (or rather absorbance) 
remained very close to baseline, increasing only slightly at 72 hours for 10 !-1M 
treated cells. However, the readings were so close to the readings at time 0 that it 
was difficult to determine whether the effect of KLM 155 at these concentrations was 











We thus performed a dose response curve plating a much higher number of cells 
(5000 per well) (Figure 3,8.). After allowing cells to settle overnight, KLM155 was 
added to quadruplicate wells at various concentrations. MTT was added to one set of 
untreated wells at this point to serve as a time 0 (indicated on the graph by a dotted 
line). After 24 hours both 5 and 10 IJM KLM155 significantly decreased cell number 
below that of untreated, but cellular proliferation had still occurred, since the readings 
were higher than those at time O. However both 20 IJM and 50 IJM KLM 155 had 
decreased cell number below that at time 0, indicating a cytotoxic effect at these 
higher concentrations, and a cytostatic (perhaps combined with cytotoxic) effect at 
the lower concentrations. 
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Figure 3.8. Death curve. WHC01 cells treated with varying concentrations of KLM155. 
Cells were plated at 5000 cells/well and allowed to settle overnight. They were then treated with 
varying concentrations of KLM155 and grown for another 24 hours. MTT reagent was then added. 
The dotted line represents the absorbance reading at time zero. Each point represents the mean 
of 4 wells, with standard deviation, and this is representative of at least two independent 











3.2.4. Effects of KLM155 and KLM156 on cell morphology 
To observe the effect of the two most active KLMs (KLM155 and KLM156) on cell 
morphology, treated cells were viewed under light microscopy, and images captured 
using a Zeiss Axiovert 200 with an Axiocam camera and Axiovision 4.1 image 
software. Several morphological features were noted (Figure 3.9.). 
The morphology of cells treated with 20 IJM KLM155 for 24 hours is distinctly different 
to that of untreated cells. Cells are shrunken and rounded, and apoptotic bodies 
displaying typical membrane blebbing were observed (Figure 3.9.E). 
Cells treated with 20 IJM KLM156 were not as obviously affected as cells treated with 
KLM155, but on closer examination the morphology of adherent cells was slightly 
altered, while there were more floating cells than in untreated. Floating cells 
appeared intact in most cases, with very few apoptotic cells observed, but a large 
proportion of the floating cells appeared as doublets (Figure 3.9.F, inset), which 
indicated that there may be a cell cycle arrest in G2/M phase. 
















Figure 3.9. Morphological changes of cells untreated, or treated with 20JjM KLM155 or 
KLM 156 for 6 and 24 hours. 
Cells were plated in 60mm dishes and after an overnight incubation to allow settling, KLM155 
and KLM156 were added at 201JM. Photographs of the cells were captured using a Zeiss 
Axiovert 200 with an Axiocam camera and Axiovision 4.1 image software after 6 and 24 hours. 
Cells with membrane blebbing were observed in cells treated with KLM155 (inset in E) and cell 











3.2.5. Effects of treatment with KLM155 and KLM156 on the cell cycle 
Cell cycle analysis was performed on cells treated with KLM155 and KLM156 to 
determine the effect these compounds might have on the cell cycle. Since we had 
observed an accumulation of cells with doublet morphology following treatment with 
KLM156, a G2/M cell cycle block was anticipated for this compound. 
At the lowest concentration of KLM155 and KLM156 (21-lM and 10 I-lM), cell number 
remained similar (KLM155), or was slightly elevated (KLM156) compared to 
untreated, and the cell cycle profiles remained unchanged. However, at 20 I-lM both 
compounds caused substantial changes in cell cycle dynamics with a 26% increase 
in the G2 phase observed after treatment with both compounds (Figure 3.10). This 
was accompanied by a decrease in cell number to almost a third of untreated cells. 
At 50 I-lM the cell cycle in cells treated with KLM156 was completely dysregulated, 
while cells treated with KLM155 retained a G2 block. 
The decrease in cell number seen at 10 I-lM in the death response curve (Figure 3.8.) 
was not observed in the cell cycle analysis. Several explanations for this can be 
considered. The first is the techniques used to measure cell number for the two 
assays differed. Cell number in the dose response curve was measured indirectly by 
MTT (reflecting metabolically active cells), while for cell cycle analYSis cells were 
harvested by trypsinisation and counted using a haemocytometer. The processes of 
trypsinisation and centrifugation may have introduced some error in the cell counts, 
however this is unlikely to explain the large difference observed. The second, and 
more likely explanation for the lack of cell killing effect seen with 10 /-1M KLM155 in 
the cell cycle experiment, is the change in cell density as a result of scaling the 
experiment up to 60 mm dishes. For the MTT experiments, cells are plated at 1500 
(or 5000) cells per well in a final volume of 100 !-II giving a density of 3750 (or 12500) 
cells/cm2 and 15 (or 50) cells/l-ll. However, for cell cycle analysis, cells are plated at 
O.5x106 cells in a 6 cm dish in a final volume of 3 ml, which gives a density of 23809 
cells/cm2 and 166 cells/l-ll. Thus the final concentration of compound per cell, and the 
density of the cells are different. Similar effects of cell density (and indeed, even 
parental culture density) have been shown to affect the toxicity of tamoxifen and 
vinblastine in culture (119). However, we can consider 20 /-1M, which decreases cell 
number to half that of untreated cultures, to be equivalent to the ICso concentration, 
and thus the cell cycle effects seen at this concentration to be indicative of those at 
























Figure 3.10. Cell cycle profiles for compounds treated with KLM155 or KLM156. 
Cells were treated for 24 hours with the indicated concentrations of KLM155 and KLM156, They 
were then trypsinised, counted (numbers in the bottom right of each plot show the number of 
surviving cells xi 05 for that treatment condition), and then processed for cell cycle analysis as 
described in Materials and Methods. The x-axis indicates the amount of fluorescence, and the y-











3.2.6. Determining the mode of cell death induced by KLM155 (apoptosis or 
necrosis) 
It was important to determine the mode of cell death induced by the KLMs. Apoptosis 
is the preferred mechanism of cell death for chemotherapeutic agents so that 
inflammatory reactions are minimized. 
Induction of apoptosis by KLM155 was assessed using a variety of techniques, all 
based on detecting the activation of the effector caspase 3. Initially an antibody 
against activated caspase 3, conjugated to a fluorescent molecule (FITe) was used 
to label cells, and fluorescence was detected by flow cytometry. Results using this 
technique indicated that 61 % of cells treated with 25 IJM KLM155 at 12 hours were 
undergoing apoptosis. These levels are similar to those induced by treatment with 
the positive control doxorubicin, while treatment with 30 IJM KLM156 resulted in 35% 
of cells undergoing apoptosis (Figure 3.11.). 
However, this technique involves considerable processing of the sample, and was 
not suitable for the large numbers of experimental conditions that would be required 











% apoptotic cells - 3% 
untreated 
% apoptotic cells - 61 % 
25j.JM KLM155 
% apoptotic cells - 35% 
30j.JM KLM156 
% apoptotic cells - 79% 
3j.Jg/ml Doxorubicin 
Figure 3.11. Apoptosis induction by KLM155 and KLM156 as measured using a 
fluorescent antibody to activated caspase-3. 
Induction of apoptosis following 12 hours treatment with KLM155, KLM156 and 3lJg/ml 
doxorubicin was measured using the Active Caspase-3 FITC Mab Apoptosis Kit (SO 
Siosciences) as described in Materials and Methods. Fluorescence was detected using flow 
cytometry. The x-axis represents fluorescence on a log scale, and the y-axis represents the 











We considered several approaches to measuring apoptosis in KLM155 treated cells, 
including DNA fragmentation, cleavage of a synthetic substrate (DEVD-AMC) to 
release a fluorescent molecule, and detection of PARP and procaspase 3 cleavage 
by Western Blot. 
The assay we eventually used to measure apoptosis was the Caspase-Glo™ 3/7 
Assay kit (Promega Cat#G8090), which relies on detection of luminescence after 
cleavage of a substrate by activated caspase 3 or caspase 7. Since the assay is 
designed for microplate format, it was suitable for a large number of sample 
conditions. 
I n a time course experiment apoptosis following treatment with 20 !-1M KLM 155 was 
observed at 9 and 24 hours, but not at 3 hours, indicating that apoptosis induction 
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Figure 3.12. Time course of apoptosis induction by KLM155 measured using the Caspase-
GloTM 3/7 Assay. 
Cells were treated with KLM155 at 20!-lM in triplicate, and at the indicated times Caspase-Glo 
reagent was added, and the luminescence read on a Lumoscan plate reader. Values are the 
mean of triplicate wells, with standard deviation indicated by the error bars. (* p < 0.05; ** P < 











Secondly we evaluated the effect of concentration on apoptosis induction . Cells were 
treated (in triplicate) with varying doses of KLM155, and after 9 hours, Caspase-Glo 
reagent was added, and the resulting luminescence measured (Figure 3.13). This 
indicated that lower concentrations of KLM155 (5 and 10 IJM) did not induce 
apoptosis after 9 hours of treatment, but that the highest concentration tested (20 




































Figure 3.13. Apoptosis induction by KLM155 at varying concentrations. 
The ability of differing concentrations of KLM155 were evaluated. Cells were treated in triplicate 
with the indicated concentrations of KLM 155 for 9 hours. Caspase-Glo reagent was added , and 
the luminescence read on a Lumoscan plate reader. Values are the mean of triplicate wells, with 
standard deviation indicated by the error bars. (* p < 0.001) . Results are representative of at least 











In order to confirm that cell death occurred only via the apoptotic pathway, and not by 
necrosis, we performed a necrosis assay using the CytoTox-ONE Homogeneous 
Membrane Integrity assay (Promega Cat#G7891) . This kit contains a reagent 
cleaved by lactate dehydrogenase, which is released when cell membrane disruption 
occurs during necrosis, but not during early apoptosis. Thus fluorescence is a direct 
measure of the number of necrotic cells present. Cells were treated (in triplicate) with 
varying concentrations of KLM155, and at the indicated time points, CytotoxONE 
assay reagent was added to each well. A positive control using lysis buffer supplied 
with the kit was performed at each time point, and results are expressed as the 
percentage of fluorescent signal obtained for the control (Figure 3.14.) . No significant 
increase in LDH activity was observed between untreated and treated cells at various 
time points. 
We also established the integrity of the plasma membrane of KLM 155 treated cells 
by examining the ability of cells to exclude trypan blue. Necrotic cells, with disrupted 
membranes would be unable to exclude trypan blue, as would cells in late apoptosis . 
Cells were treated, and at several time points, replicate wells were stained with 
trypan blue and examined for the presence of dead cells. None were observed (data 
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Figure 3.14. Necrosis induction by KLM155 at varying concentrations and times. 
The ability of differing concentrations of KLM155 to induce necrosis were evaluated. 
Triplicate wells were treated, and at the indicated time points CytotoxONE reagent was 
added. Fluorescence was then measured using a fluorescence plate reader. Values are the 
mean of triplicate wells, with standard deviation indicated by the error bars. This result is 












All the KLMs tested were soluble in aqueous solution and cytotoxic to the cell line 
used for screening (WHC01) with IC50 concentrations below 100 IJM. Compounds 
KLM1 and KLM156 of this family displayed considerable activity against cultured 
oesophageal cancer cells, with IC50 values of 9.8 IJM and 12.9 IJM, respectively. This 
compares favourably to the commonly used chemotherapeutic agent cisplatin, which 
has an IC50 value of 13 IJM against WHC01 (90). 
Further IC50 experiments were performed with the most active compound (KLM155) 
against a range of cell lines, including another oesophageal cancer cell line 
(WHC06), two cervical cancer cell lines (SiHa and ME180), and the breast epithelial 
line (MCF12A). KLM155 shows similar activity for the two oesophageal cancer cell 
lines, while the cervical cell line, ME180, and the breast epithelial line, MCF12A, 
were slightly less sensitive. The cervical cancer cell line, SiHa, was resistant to 
KLM155 up to the highest concentration tested (150 IJM). 
We showed that these compounds induce apoptosis, and this is consistent with other 
reports that quinone and hydroquinone compounds induce apoptosis in cancer cell 
lines. The natural anthroquinone derivative, emodin, has been shown to induce 
apoptosis in human lung adenocarcinoma cells (120), 4-hydroxyestradiol was found 
to induce apoptosis in human mammary epithelial cells (121) and two marine 
quinones, isolated from the Mediterranean ascidian Aplidium conicum were also 
shown to induce apoptosis in a lymphoma cell line (122). All these compounds 
induced apoptosis via the mitochondrial pathway following the production of reactive 
oxygen species. 
Considering all our results obtained in the 96-well plate format (ICsa data, growth and 
death curves, and apoptosis and necrosis data) it appears that at low doses (5 and 
10 IJM) KLM155 reduces cell number in comparison to untreated by causing a 
decrease in cell proliferation, rather than cell death. At higher concentrations (20 IJM), 
KLM155 clearly decreases cell number below that plated initially, and apoptosis is 
detected at these concentrations, 
In cell cycle analysis, a larger format was used, and due to scaling of the experiment, 
a greater density of cells was used. Previous work has shown that plating density 











for the different sensitivity of these cells (as measured using cell counting) to 
KLM155 in this format. If we consider the concentration of KLM155 that reduces cell 
number in the 60 mm dish by 50% to be roughly equivalent to the ICso concentration, 
then we can equate the cell cycle changes (accumulation of cells in G2) at 20 IJM 
KLM155 to the results obtained in 96-well plate format at 10 jJM. 
The comparative simplicity of these compounds, and the close structural 
relationships between them allowed us to make some tentative conclusions 
regarding the contribution of the different chemical moieties to the toxicity of these 
compounds. The central quinone/hydroquinone structure plays a key, consistent role 
in activity, which is consistent with previous observations of similar compounds (116). 
While the cell lines used in this paper differ from those used by Li et al. (116), this 
observation may be of use in rational drug design, and is likely to be linked to either 
the potential of these compounds to produce reactive oxygen species, or to the 
rearrangement of these compounds into alkylating agents. 
The configuration and substitutions on the triprenyl side chain were also important, 
as evidenced by the superior activity of the all trans chain (KLM155) over the 
trans,cis chain (KLM156), and the hydroxyl sUbstitution over the carbonyl (KLM159 
vs KLM 155). These differences in activity may be due to altered stability of the 
molecules, or due to altered specificity for enzymes. 
Considering that KLM155 clearly induced apoptosis in oesophageal cancer cells, and 
that sufficient quantities of this compound were available, we embarked on another 












ROLE OF OXIDATIVE STRESS IN THE ACTIVITY 
OF THE KLMs 
4.1. Introduction 
Having determined that the KLMs induce apoptosis in oesophageal cancer cells, we 
investigated the role of oxidative stress in the activity of these compounds. Current 
evidence suggests that the commonly used chemotherapeutic agents doxorubicin 
(which contains both quinone and hydroquinone moieties) and paclitaxel induce cell 
death at least in part through the production of reactive oxygen species (62;63;65). 
The potential of the KLMs to be involved in redox type reactions was confirmed when 
the literature was examined for similar compounds (120-125). 
Despite the widespread use of quinone compounds in cancer chemotherapy, the 
contribution of the quinone moiety to the activity of these compounds remains to be 
fully elucidated, since most of these compounds contain other structural moeitiesthat 
may also contribute to the biological activity (117). We hoped that by elucidating the 
action of the KLMs, which are relatively simple compounds, we could determine the 
contributions of the quinone and the side chain to ROS generation and activity. 
4.1.1. Experimental approach 
We tested the ability of the KLM155 to produce ROS, using the fluorescent probe 
DCF-DA. Having confirmed production of ROS by this compound, we evaluated the 
levels of ROS produced by all the compounds, and correlated this to the activity 
measured in Chapter 3. To evaluate the contribution of ROS production to cell death, 
we treated cells with KLM155 in the presence and absence of the ROS scavengers 
BHA and Trolox, and assessed cell survival and apoptosis. 
As a further confirmation that the KLMs induced oxidative stress, we performed 
microarray analysis in KLM155 treated cells. The majority of the genes we identified 
as being upregulated were involved in antioxidant response pathways or repair of 











To establish the pathways by which these genes are upregulated, and by which 
apoptosis occur, we examined the signaling of various stress response pathways in 
response to KLM treatment and identified c-Jun as being upregulated. Further 
experiments inhibiting signaling via the JNK stress signaling pathway were performed 












4.2.1. Production of reactive oxygen species in response to KLM treatment 
We used the ROS sensitive probe 2',7'-dichloro-fluorescein diacetate (DCF-DA) to 
measure ROS generation in KLM treated cells. This compound is a cell-permeant 
indicator for reactive oxygen species that is nonfluorescent until the acetate groups 
are removed by intracellular esterases and oxidation occurs within the cell(126;127). 
It detects the presence of hydrogen peroxide and multiple radicals - the peroxyl and 
hydroxyl in particular. Experiments were carried out by pretreating WHC01 cells with 
DCF-DA, then treating with KLM155, and visualizing fluorescence using a fluorescent 
microscope. A dose dependant generation of reactive oxygen species could be 
observed (Figure 4.1.). Cells treated with higher concentrations of KLM155 and 
KLM156 had more cells fluorescing, and brighter fluorescence than cells treated with 
lower concentrations, or untreated cells. However this protocol is very sensitive to 
temperature, pH and light, and the results were hard to quantitate and reproduce, 











Figure 4.1. ROS production in cells treated with KLM155 and KLM156. 
To determine if treatment ofWHC01 cells with KLM155 and KLM156 induces ROS production, 
cells were pretreated for 15 minutes with the 'fluorescent probe DCF-DA (25IJM). They were 
then incubated with KLM155 or KLM156 at 5 or 20IJM for 30 minutes, and fluorescence 
observed using a Zeiss Axiovert 200 with an Axiocam camera and Axiovision 4.1 image 












A similar protocol was established where cells were pretreated for 15 min with DCF-
DA and the resulting fluorescence following treatment with KLMs was measured 
using a flow cytometer. This allowed quantification of the levels of fluorescence (and 
thus reactive oxygen species) in each cell. This approach has been used previously 
to measure ROS production in cancer cells following treatment with a range of 
chemicals (121;128). 
Initial experiments to measure the levels of ROS in cells treated with KLM155 
indicated generation of reactive oxygen species at higher concentrations, with ROS 
generation at 20 fJM three fold higher than that of untreated cells (Figure 4.2.). ROS 
generation at 5 fJM was not significantly different from that of untreated cells, while a 
slight increase (1.3 fold) was noted at 10 fJM (p<0.05). Of particular interest, this 
pattern of ROS production resembled the pattern of apoptosis induction at the same 
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Figure 4.2. ROS generation by KLM155 in WHC01 cells. 
** 
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Cells were pretreated with 25fJM DCF-DA for 15 minutes, and then treated with the indicated 
concentrations of KLM155. After 1 hour, cells were harvested by trypsinisation, and 
fluorescence was assessed by flow cytometry. Values are the mean of three replicates with 












A time course of ROS production, using 20 IJM KLM155 revealed that reactive 
oxygen species were generated as early as 15 min after treatment, and increased up 
to 2 hours (the limit of the experiment) (Figure 4.3.). 
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Figure 4.3. Time course of ROS generation by 20jJM KLM155 in WHC01 cells. 
Cells were pretreated with 25IJM DCF-DA for 15 minutes, then treated with 20l-lM KLM155 
for the indicated times. Pretreatment and treatment were staggered to allow harvesting (by 
trypsinisation) at the same time. Fluorescence was assessed by flow cytometry. Values 
are the mean of 3 replicates with standard deviation. This result is representative of at 















We proceeded to test whether the other KLM compounds produce ROS, by testing 
the levels of ROS generated by each compound at 20 ~M. Not only did all the KLM 
compounds generate reactive oxygen species to a greater or lesser extent, we also 
observed a correlation between the levels of ROS and the activity of each compound. 
The correlation showed that the more active compounds generated more ROS than 
less active compounds. A plot of the IG50 values for each compound against the 
levels of ROS generated at 20 IJIVl showed a direct correlation between ROS 
generation and activity (Figure 4.4.) with an R2 value of 0.67. If we consider KM158 
as an outlier (since its structure differs substantially from the other compounds), and 
exclude it from the analysis, the R2 value improves to 0.83. This indicates a strong 
correlation between activity (as measured by IG50 values) and ROS production. 
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Figure 4.4. Correlation of IC so concentration with ROS generation. 
The IGso for each compound (as determined by dose response curves, Table 3.2) was 
correlated with the level of ROS produced by that compound at 20l-1M (measured using DCF-
DA and flow cytometry as outlined in Materials and Methods). A linear relationship between the 
two exists, with an R2 value of 0.67. If the outlier KLM158 is excluded from the analysis, the R2 
value improves to 0.83, indicating a strong correlation between IGso and ROS production. The 











4.2.2. Inhibition of ROS production by the scavengers Trolox and BHA 
To confirm whether the cell death observed was mediated via production of ROS, we 
treated cells in the presence and absence of the ROS scavengers Trolox (100 IJM) 
and BHA (100 IJM) and assessed the cells for apoptosis and survival. 
When ROS scavengers were added to cells prior to treatment with KLM155, a 
reduction in caspase 3 activity was observed, with BHA decreasing activity by 73% 
(p<0.01) and Trolox decreasing caspase 3 activity by 66% (p<0.05) (Figure 4.5.). 
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Figure 4.5. Inhibition of KLM155 induced apoptosis by addition of ROS scavengers. 
Cells were pretreated with the ROS scavengers Trolox or BHA, and then treated with KLM 155 
at 20iJM. For each condition of scavenger, one set of wells (in quadruplicate) were treated, 
and one set used as control. Apoptosis was assessed using the Caspase-Glo kit after 24 
hours of treatment, and values were expressed as fold increase in apoptosis relative to the 
KLM-untreated control for each scavenger. Values are the mean of triplicate wells, and error 
bars indicate standard deviation. (* p<0.01, ** p<0.05). This result is representative of at least 











A significant increase (p<O.01) in the survival of celis treated with the ROS scavenger 
Trolox and KLM 155 was observed, compared to cells treated with KLM 155 alone 
(Figure 4,6). While a similar trend was observed with BHA, this effect was not 
significant (p=O.1) The lack of correlation between decrease in apoptosis and 
increase in cell number for BHA treated cells needs to be explored further. The effect 
of BHA and Trolox on KLM155 mediated cell death was tested in at least two 
separate experiments with similar results to those reported in Figure 4.6. 
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Figure 4.6. Prevention of KLM155 induced cell death by the addition of ROS scavengers. 
Cells were pretreated with the ROS scavengers Trolox or BHA, and then treated with KLM155 
at 201JM. For each condition of scavenger, one set of wells (in quadruplicate) were treated, and 
one set used as control. The number of remaining cells was assesed using the MTT assay after 
24 hours, and these values expressed as percentage of the KLM untreated control for each 
condition. Values are the mean of quadruplicate wells, and error bars indicate standard 











4.2.3. Transcriptional changes following treatment with KLM155 
Our findings that KLM 155 mediates cell death by producing ROS, suggested that a 
number of antioxidant mechanisms might be activated in order to respond to the 
oxidative stress. To further confirm that KLM treatment induced oxidative stress, we 
performed microarray analysis to evaluate the transcriptional response of WHC01 
cells to KLM155 treatment. This could provide information about a variety of 
antioxidant response and repair systems that may be induced by KLM 155 treatment. 
RNA for gene expression analysis was prepared from three replicate dishes of 
WHC01 cells treated with 20 IJM KLM155. Untreated controls in triplicate served as 
controls. After treatment, each dish was harvested separately using Trizol reagent to 
isolate total RNA. mRNA was amplified, labeled with Cy5 dye, and used in 
microarray analysis. An array was performed for each sample, with a human 
reference RNA sample (labeled with Cy3 dye) consistant across the arrays. Arrays 
were scanned and results generated in GenePix Pro upload d into the NCI 
microarray database (MaDS) for further analysis. 
Comparisons of genes with altered expression between the untreated and KLM1 
treated groups revealed a number of genes at a p value of 0.05. 
A total of 179 genes were identified as having altered expression in KLM 155 treated 
cells compared to untreated cells. Restriction of the list to genes that were either 1.5 
fold upregulated or 1.5 fold downregulated, limited the number to 23 genes of which 












Gene Description Fold up Fold down p-Value 
H01 heme oxygenase (decycling) 1 8.13 0.12 0.00465 
TXNRD1 Thioredoxin reductase 1 2.69 0.37 0.018 
Human DNA sequence from clone RP5-1103G7 on 
chromosome 20p12.2-13. 3.66 0.27 0.01846 
FTH1 Ferritin , heavy polypeptide 1 1.64 0.61 0.02137 
Ubiquinol-cytochrome c reductase, complex III subunit VII , 
UQCRQ 9.5kDa 1.76 0.57 0.0373 
ATP synthase, H+ transporting , mitochondrial F1 complex, 
ATP5C1 gamma polypeptide 1 1.61 0.62 0.03665 
Sarcoglycan, beta (43kDa dystrophin-associated 
SGCB glycoprotein) 1.65 0.61 0.00786 
ATP synthase, H+ transporting , mitochondrial F1 complex, 
alpha subunit , isoforrn 1, card iac muscle 1.64 0.61 0.02647 
DSTN Oestrin (actin depolymerizing factor) 1.53 0.65 0 .02278 
ELM01 Engulfment and cell motility 1 1.61 0.62 0.04964 
PAX3 Paired box gene 3 (Waardenburg syndrome 1) 1.62 0.62 0.02833 
UBE2L3 Ubiquitin-conjugating enzyme E2L 3 1.63 0.61 0.00437 
WFS1 Wolfram syndrome 1 (wolfram in) 1.56 0.64 0.03453 
FLJ38973 Hypothetical protein FLJ38973 0.65 1.53 0.00038 
FABP7 Fatty acid binding protein 7, brain 0.6 1.66 0.03449 
Signal sequence receptor, alpha (translocon-associated 
SSR1 protein alpha) 0.6 1.67 0.0429 
Unknown 0.61 1.63 0.04346 
TTRAP TRAF and TNF receptor associated protein 0.6 1.66 0.01011 
RPS6KA1 Ribosomal protein S6 kinase, 90kDa, polypeptide 1 0.52 1.94 0.01314 
Pleiotrophin (heparin binding growth factor 8, neurite 
PTN growth-promoting factor 1) 0.6 1.66 0.02898 
ESTs 056 1.78 0.01804 
RPL7 Ribosomal protein L7 055 1.82 0.04828 
HSP90B1 Heat shock protein 90kDa beta (Grp94) , member 1 0.47 2.11 0.04695 
DDIT3 DNA-damage-inducible transcript 3 1.32 0.76 0.00655 
Table 4.1. Genes up or down regulated in response to KLM155 treatment. 
Microarray analysis was performed on triplicate untreated and treated (20~M KLM155 for 8 
hours) samples, and data were analysed using MaDS software. This table presents the genes 
identified to be differentially expressed between treated and untreated samples, with a 
significant (p<O.05) increase or decrease in expression greater than 1.5 fold. The fold 
difference has been presented as both fold up (treated/untreated) and fold down 
(untreated/treated) in treated samples . The final gene identified (DNA-damage-inducible 












Of these 23 genes, we selected four that were considered to be of most interest to 
validate using quantitative real-time RT-PCR. We chose genes that are involved in 
cellular stress responses, and were highly (>2 fold) up- or down-regulated in our 
array results. These were heme oxygenase 1, thioredoxin reductase, GADD34 (DNA 
damage inducible transcript 3) and HSP90. We also decided to evaluate the 
expression of two antioxidant genes (MnSOD and glutathione reductase), the 
quinone metabolizing enzyme, NQ01, and the molecular chaperone HSP70 (since 
another molecular chaperone, HSP90, was downregulated). GAPDH was used as 
the housekeeping gene for normalization. 
Sequence and PCR conditions for each gene are in Table 6.3. in Materials and 
Methods. Real time PCR was carried out using the LightCycier FastStart DNA Master 
SYBR Green I reaction mix (Roche) on a LightCycler Instrument (Roche), and results 
were normalized using the 2-MCT method (129). 
Heme oxygenase 1 is involved in the breakdown of heme, which is released from 
heme-containing enzymes when they are damaged by ROS (130). The gene for 
heme oxygenase showed the most upregulation on the array, with an 8 fold increase 
in treated compared to untreated cells (p = 0.005). Real time RT-PCR confirmed this 
upregulation (Figure 4.7.). In fact, the level of upregulation was much higher than that 
initially indicated by the microarray data with an upregulation of 102.7 fold (p = 0.002) 
over untreated. 
The thioredoxin system is an antioxidant defense system. Thioredoxin is easily 
oxidized by ROS, and is then reduced by thioredoxin reductase, with NADPH as a 
cofactor (131). The gene for thioredoxin reductase was upregulated 2.7 fold in our 
array data (p = 0.018), and real time RT-PCR confirmed this upregulation, with a 2.6 
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Figure 4.7. Microarray and Real time RT-PCR analysis for Heme oxygenase. 
RNA from untreated and treated (20iJM KLM155 for 8 hours) cells was analysed by microarray 
or quantitative real-time RT -PCR for the gene encoding heme oxygenase. Each bar represents 
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Figure 4.8. Microarray and Real time RT-PCR analysis for Thioredoxin reductase. 
RNA from untreated and treated (20iJM KLM155 for 8 hours) cells was analysed by microarray 
or quantitative real-time RT-PCR for the gene encoding thioredoxin reductase. Each bar 











GADD34 (DNA damage inducible transcript 3) is induced in response to cell cycle 
arrest and DNA damage (ref 2 in Morton, 2006), plays a role in preventing protein 
synthesis under stress conditions, and can also suppress cell growth (132), Even 
though this gene was below the cut-off of 1.5 fold up or down regulated, we included 
it in the analysis because it was significantly upregulated (p = 0.007), and the 
biological action of the product of this gene may have some relevance in the action of 
the KLMs on cells. Real-time RT-PCR analysis showed much higher activation of this 











Microarray Real-time RT-PCR 
Figure 4.9. Microarray and Real time RT-PCR analysis for GADD34. 
20jJM KLM155 
RNA from untreated and treated (201JM KLM155 for 8 hours) cells was analysed by microarray 
or quantitative real-time RT-PCR for the gene encoding DNA-dam age-inducible transcript 3 
























The heat shock proteins play key roles in protein folding and in stress responses, and 
prevent misfolding and aggregation of damaged proteins (133).The chaperone 
HSP90 was downregulated 2 fold (p = 0.047) in our microarray analysis, but real-time 
RT-PCR analysis did not show a significant difference between untreated and 
KLM155 treated cells. However, we also determined the expression of HSP70 in 
treated and untreated cells using real-time RT-PCR and determined that HSP70 
expression was upregulated 2.8 fold (p = 0.025) (Figure 4.10.), 
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Figure 4.10. Microarray and Real-Time RT-PCR analysis for HSP90 (A) and Real-Time 
RT -PCR analysis for HSP70 (B). 
RNA from untreated and treated (201JM KLM155 for 8 hours) cells was analysed by microarray 
or quantitative real-time RT-PCR for the genes encoding HSP90 and HSP70. Each bar 











We evaluated the expression of two genes encoding antioxidant enzymes -
manganese SOD (MnSOD) and glutathione reductase. We hypothesized that since 
the KLM155 causes the production of ROS, cells treated with this compound may 
increase levels of antioxidant proteins in order to combat this stress. However, 
neither of these genes showed any significant alteration in expression following 

































Real-time RT -PCR 
Figure 4.11. Real-Time RT-PCR analysis for MnSOD (A) and Glutathione reductase (8). 
RNA from untreated and treated (20~M KLM 155 for 8 hours) cells was analysed by 
quantitative real-time RT-PCR for the genes encoding MnSOD and Glutathione reductase. 











Finally we examined the levels of N001 in response to treatment with KLM155, 
N001 is a metabolic enzyme that metablises quinones via a two electron reduction 
into the corresponding hydroquinone, This is often a detoxifying step, but in some 
cases the hydroquinone is more toxic that the parent quinone. NQ01 was 



















Figure 4.12. Real~Time RT-PCR analysis for NQ01. 
RNA from untreated and treated (201JM KLM155 for 8 hours) cells was analysed by 
quantitative real-time RT-PCR for the gene encoding N001. Each bar represents the mean of 











4.2.4. Effect of KLM treatment on signal transduction pathways 
The previous sections have convincingly demonstrated that KLM155 treatment of 
cells is associated with the generation of ROS. The production of ROS in cells is 
often associated with the activation of stress signaling pathways like the MAPK 
kinase pathways, e.g. JNK or p38 (Figure 4.13.) (128;134-136) . This can lead to the 
upregulation of antioxidant response genes, or to cell death, depending on the 
duration and intensity of ROS exposure (136). Since we had observed upregulation 
of a number of stress response genes, we determined whether the ROS production 
induced by KLM treatment leads to activation of the stress signaling pathways most 
























Figure 4.13. The ERK, p38 and JNK·MAPK signalling pathways. 
Signal transduction through the MAPK pathways occurs by the sequential activation by 
phosphorylation of a series of kinases. The effector molecules (Mitogen activated protein 
kinases, or MAPKs) are activated by MAPKK (MAPK kinase), which in turn was activated by a 











Protein Iysates from cells treated with varying concentrations of KLM 155 were 
harvested at 6 and 24 hours after treatment. The levels of phosphorylated p38 (p-
p38) and c-Jun in these Iysates was evaluated using Western blot analysis (Figure 
4.14.). c-Jun levels increased in treated cells in a concentration dependant manner at 
both 6 and 24 hours (Figure 4.14.A.). While p-p38 levels in KLM 155 treated cells 
increased to almost 3 times as high as in untreated cells after 24 hours of treatment, 
levels in both treated and untreated cells were extremely low in comparison to a 
positive control of protein Iysates from UV treated cells included on the blot (Figure 
4.14.B., lane 9). 
c-Jun is known to be both pro- and anti-apoptotic depending on the cellular 
environment and other signals, and regulates antioxidant genes among others, 
enabling the cell to deal with the damage caused by ROS. Upregulation of c-Jun was 
observed even at concentrations where ROS levels were low, and cell death did not 
occur, indicating that c-Jun may have different effects at low and high concentrations 
of KLMs. The effects of c-Jun are known to vary depending on the duration and 
intensity of the signaling via the JNK pathway under conditions of stress (136). 
While we demonstrated increased levels of c-Jun, we did not examine levels of 
phosphorylated c-Jun since there is evidence in the literature to show that 
upregulation of c-Jun corresponds with an increase in activity (137;138), and our 
examination of the transcriptional profile of KLM155 treated cells had strongly 
indicated activation of either the JNK or p38 signaling pathway. 
We used total ERK1/2 as a loading control since levels of other housekeeping genes 
(tubulin, actin) are known to vary during the cell cycle, and would thus be altered in 
treated cells undergoing a cell cycle block. We also confirmed equal protein loading 
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Figure 4.14. Analysis of MAPK signalling molecules c-jun (A) and p-p38 (8) in KLM155 
treated cells. 
The levels of the MAPK signalling molecules c-jun (A) and p-p38 (B) were analysed by Western 
Blot. Cell Iysates from cells treated with the indicated concentration of KLM 155 were harvested 
at 6 and 24 hours and analysed by Western Blot (as outlined in Materials and Methods). Blots 
were stripped and reprobed for total ERK1/2. Bands on the autoradiographs were quantitated by 
densitometry, using total ERK1/2 as a loading control. The positive control in B is cell lysate 
from UV irradiated Cos cells (kindly provided by A. Abrahams, University of Cape Town, South 











4.2.5 Effect of Inhibition of c-Jun activity on KLM155 treated cells 
To test whether the cell death observed was mediated via signaling through c-Jun we 
adopted two approaches. In the first, we used a chemical JNK inhibitor II 
(Calbiochem Cat#420128), that inhibits JNK activity such that phosphorylation of c-
Jun does not occur (139). As an independent confirmation of the effects noted with 
the JNK inhibitor, we used a cell line transfected with the dominant negative mutant 
of c-Jun, TAM67, that inhibits c-Jun function and compared the effect of KLM1 on 
parental and tranfected cells. 
4.2.5.1. Inhibition of JNK:c-Jun signaling using a chemical inhibitor of JNK 
Inhibition of JNK using JNK inhibitor II significantly decreased apoptosis by 55% 
compared to KLM155 treatment alone (p<O.05) (Figure 4.15.A). JNK inhibition 
however, had no effect on cell survival in the presence of KLM155 (Figure 4.15.B.). It 
is possible that the concentration of ~INK inhibitor used was insufficient to completely 
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Figure 4.15. Inhibition of KLM155-induced apoptosis (A) and effect on KLM155-induced 
cell death (8) by the addition of JNK inhibitor II. 
Cells were pretreated with JNK inhibitor II (100jJM), and one set of wells (in quadruplicate) was 
treated with KLM155, and one set used as control. After 24 hours, cells were assessed for either 
apoptosis, using the Caspase-Glo 3/7 kit (A), or cell death/survival, using MTT (B). These 
values were expressed as fold (A) or percentage (8) of the KLM untreated control for each 
condition. Values are the mean of triplicate (A) or quadruplicate (8) wells, and error bars 














Inhibition of c-Jun activity with a dominant negative construct 
We tested whether abolishing 
the expression/activity of AP1 
(specifically c-Jun) using the 
dominant negative TAM6?, 
could alter the response of a 
cell line to the KLMs. T AM6? is 
a dominant negative mutant of 
c-Jun which lacks amino acids 
3-122, removing the 
transactivating domain. TAM6? 
dimerised with wild-type c-Jun, 
but since it lacks the 
transactivation domain, the 
dimers comprising c-Jun and 
TAM6? are unable to 
transcriptionally activate any 




Figure 4.16. Inhibition of c-jun using a dominant 
negative construct. 
The structure of c-jun and T AM6? c-jun consists of 
a transactivating domain (TA), a DNA binding 
domain (DBD) and a leucine zipper domain (LZ). 
TAM67 lacks amino acids 3-122, removing the 
transactivating domain. TAM6? dimerises with wild-
type c-jun, but since it lacks the transactivation 
domain, it blocks activity of the wild-type c-jun. 
(Adapted from Hennigan et al. (140» 
A doxycycline-inducible TAM67 expressing cell line, CaskilTAM67, was obtained 
from M.Maritz (Honours thesis, University of Cape Town, 2005). The effect of 
KLM155 treatment on the parental cells, Caski and Caski-TAM67 grown in the 
presence of doxycycline was determined. Expression of the inhibitor of c-Jun, 
TAM67, resulted in the cells being slightly more resistant to KLM 155 (lC5o = 28 IJM, 
95% CI 23.2 - 34.6), compared to the parental Caski cells (IC50 = 21 IJM, 95% CI 
18.7-25.1). 
In addition, cell survival following treatment was increased in both the uninduced 
(82% survival) and induced (100% survival) CaskiITAM67 cell line in comparison to 
the parental line (53% survival) (Figure 4.17.A). The increase in survival compared 
to the parental line is significant (p<0.01), even in the case of uninduced 
CaskiITAM67 cells. The increased survival observed in the undinduced CaskiITAM67 
cells is likely due to leaky expression of TAM67 in the absence of doxycycline. This 











in the uninduced cell lysate, and increased expression in the doxycycline treated 
cells (Figure 4.17.B.). 
Taken together, these results suggest that inhibition of c-Jun activity with a dominant-
negative mutant interferes with the growth inhibitory and cytotoxic effects of KLM155 
and provides further evidence that KLM155 acts via the activation of the JNK:c-Jun 
signal transduction pathway. 
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Figure 4.17. Effect of Tam67 on KLM155 induced cell death . 
Caski, uninduced CaskiITAM67 cells and induced CaskiITAM67 cells in 96 well plates were 
treated with 20IJM KLM155 or solvent control, and grown for 24 hours. Cell survival was then 
assessed using the MTT assay according to Materials and Methods. Values are the mean of 
quadruplicate wells, and are expressed as a percentage of the untreated for that cell line (A). 
Error bars indicate standard deviation. To confirm that the increased cell survival observed 
for uninduced CaskilT AM67 cells was due to basal transcription of the TAM67 construct, we 
harvested protein from treated and untreated cells from Caski, uninduced CaskiITAM67 and 
induced CaskiITAM67 celis, and ran a Western Blot (according to Materials and Methods) to 
detect TAM67 (B). The presence of a band in uninduced cells confirms basal expression of 












4.3.1. Generation of ROS by KLMs 
Compelling evidence in the literature shows that ROS plays a central role in the anti-
proliferative activity of other agents that have potential as anti-cancer agents 
including; i) 4HPR in head and neck squamous carcinoma cell lines (141), ii) diallyl 
disulfide in neuroblastoma cells (142), iii) paclitaxel in T24 urothelial carcinoma cell 
lines (65), and iv) heteroarotinoids in HNSCC cell lines (143). We hypothesized that 
the group of compounds discussed here act by generating ROS based on their 
structures. We thus evaluated the ability of KLM155 to generate ROS in WHC01 
cells, and determined that ROS is generated in response to KLM treatment In fact, 
the pattern of ROS generation seems to match that of apoptosis induction no/low 
levels at the lower concentrations (5 and 10 !-1M), and induction at 20 !-1M. This led us 
to make the tentative conclusion that ROS generation is the causative event in 
KLM155 induced apoptosis. Following this result we tested the time course of ROS 
production. ROS was generated as early as 15 min after treatment, and levels 
increased up to 2 hours, which was the limit of the assay. The rapid production of 
ROS, with ROS levels increasing prior to apoptosis induction, was consistent with our 
hypothesis that ROS production may be a causative event in KLM-induced 
apoptosis. This was supported by our observation that the addition of ROS 
scavengers BHA and Trolox could both decrease levels of apoptosis and improve 
cell survival after treatment with KLM155 for at least one of the scavengers used 
Although BHA treatment substantially blocked KLM155-induced apoptosis, no effect 
was observed on cell survival. This result requires further investigation. 
To confirm that the production of ROS was a feature of the entire group of 
compounds, all the KLMs were assayed against WHC01 cells at 20 jJM. ROS 
production varied among the compounds, but appeared to correlate with activity. This 
was observed by a plot of ROS production at 20 !-1M (in WHC01s) against the IC50 
values for these compounds in WHC01 cells. A linear relationship was observed, 
which strengthened our hypothesis that KLM treatment induces apoptosis as a 
consequence of ROS production. A similar correlation between antioxidant capacity 
and sensitivity of various cell lines to paclitaxel has been observed (65). 
Our observation that ROS production is a relatively early event (within 15 min) is 











with a variety of compounds that block cell growth and induce apoptosis through 
ROS-mediated pathways (141;142). 
Of all the cell lines tested in this study, SiHa cells were the only line resistant to KLM 
treatment. SiHa cells have been reported to have high constitutive levels of 
antioxidant enzymes (124), leading us to theorise that any ROS produced by 
KLM155 in these cells would be efficiently scavenged, hence the resistance of these 
cells to KLM155. This also adds strength to our hypothesis that the KLMs induce cell 
death by producing ROS in the cells. 
4.3.2. Mechanism of ROS production by KLMs 
At this point, with our knowledge of the metabolism of quinone type compounds, it 
was possible to develop a model to explain the differences in activity between the 
compounds. To build the case for the model we are developing, the following 
background is provided. The KLMs are quinone and hydroquinone structures (with 
the exception of KLM 157 and KLM158). Metabolism of quinones is by either a one or 
two electron reduction to form a semiquinone or hydroquinone, respectively. The one 
electron reduction can be catalysed by a range of enzymes including 
NADPH:cytochrome p450 reductase, NADPH:cytochrome b5 reductase and 
NADPH:ubiquinone oxidoreductase. The reactive semiquinone intermediate formed 
as a result of this reduction, can either revert back to the quinone, producing ROS in 
the process, or undergo another one electron reduction to form the hydroquinone. 
Quinones can also be metabolized by NADPH:quinone oxidoreductase 1 (NQ01 or 
DT-diaphorase), which performs a two electron reduction, resulting in the 
corresponding hydroquinone (Figure 4.18.) (118). The hydroquinone may 
autooxidise to form the semiquinone. Depending on the microenvironment and the 
properties of the quinone, an equilibrium between quinone, semiquinone, and 
hydroquinone will be established (117). 
Quinones are generally considered to be more cytotoxic than their hydroquinone 
metabolites. However, this is highly dependant on the structure, stability and 
reduction potential of the quinone/hydroquinone pair. In many cases the 
hydroquinone is less reactive than the quinone, and is metabolized and excreted. 
However, the hydroquinone can be more active than the quinone. rearrangement of 
the hydroquinone can occur, giving rise to an alkylating agent, and the hydroquinone 











generating reactive oxygen species. In fact, several antitumour quinones (e.g. 
mitomycin C (144;145) and 17-AAG (146;147» have been shown to require 
enzymatic reduction to the active species, generally via a two electron reduction to 





























Quinones may be metabolised by either a one or two electron reduction. One electron 
reduction may be catalysed by a variety of enzymes, including NADPH:cytochrome p450 
reductase and NADPH:cytochrome b5 reductase, and give rise to the reactive semiquinone. 
The two electron reduction is carried out by NADPH:quinone oxidoreductase 1 (NQ01), and 
gives rise to the corresponding hydroquinone. 
The hydroquinone may be metabolised and excreted, but may also be toxic. The hydroquinone 
can autooxidise to form the semiquinone, and the resulting redox cycle generates reactive 
oxygen species. The hydroquinone may also form an alkylating agent which can then damage 











Our results show that the hydroquinone KLMs (KLM155 and KLM156) are more 
active than the quinones (KLM153 and KLM154). This leads us to believe that the 
conversion of hydroquinone to the semiquinone is the most favoured reaction, and 
allows us to formulate a tentative model for the generation of ROS by these 
molecules (Figure 4.19.). 
4.3.2.1. KLM quinone (KLM153 and KLM154) metabolism 
The KLM quinones are converted to both the semiquinone and to the hydroquinone, 
which then autooxidises to the semiquinone (Figure 4.19,A). This generates ROS 
from the autooxidation of a portion of the total molecules, while the one electron 
reduction does not generate ROS. 
4.3.2.2. KLM hydroquinone (KLM155 and KLM156) metabolism 
However, the KLM hydroquinones can only be autooxidised to form the semiquinone 
(Figure 4.19.B.), thus generating more ROS the the metabolism of the quinone. 
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Figure 4.19. Metabolism of the KLM quinones (A) and hydroquinones (B). 
Metabolism of the KLM quinone structures is via both one and two electron reductions, 
generating ROS when the resulting hydroquinone is autooxidised to form the semiquinone (A). 
However the KLM hydroquinones can only be autooxidised to form the semiquinone, thus 













It is difficult to predict the dynamics of these reactions - both the metabolism of the 
quinone to the hydroquinone by NQ01, and the stability of the hydroquinone -
without performing in vitro studies with purified enzyme, and determining the 
reduction potentials of the quinone/hydroquinone pairs. Currently we have insufficient 
compounds to perform these analyses, but our collaborators are in the process of 
developing a synthesis protocol to produce large amounts of the KLMs, and related 
molecules with which we can analyse the relative contributions of the various 
substitutions and side chain length to the activity of these compounds. 
The observation that the KLMs with bent chains (KLM154 and KLM156) are less 
active than the KLMs with straight chains (KLM153 and KLM155) may reflect differing 
selectivity of N001 for different substrates, though this would not explain the 
difference in activity between the hydroquinone structures, which would not need 
activation by NQ01. A more likely explanation is that the altered conformation of the 
side chain may stabilize the hydroquinone, preventing autooxidation to the 
semiquinone, and reducing the amounts of ROS produced. 
The decreased activity of KLM159 in comparison to KLM155, which differs only in a 
hydroxyl substituted for the carbonyl on the triprenyl side chain, may be attributable 
to the same factors - altered activity for the compound by N001, or increased 
stability of the hydroquinone, leading to lower generation of ROS. 
If we accept the hypothesis that the KLM Quinones are metabolised to the active 
hydroquinones, this has implications for therapy. N001 has been shown to be 
upregulated in some cancer cells (148;149), and this would increase the sensitivity of 
these tumours to the KUvl quinones, compared to normal tissue. This is a basis for 












4.3.3. Effects of ROS production 
The production of ROS in cells is a normal cellular event, and is a consequence of a 
variety of cellular processes such as oxidative phosphorylation and the electron 
transport chain. However large amounts of ROS can cause damage to every 
constituent of the cell, including DNA, RNA, proteins and lipids (151; 152). The cell's 
response to this damage is generally to attempt repair (frequently associated with a 
cell cycle block), followed by cell death if the damage is irreparable (136;153;154). 
The cellular events we observe following treatment with KLM155 - namely cell cycle 
arrest and apoptosis are characteristic of ROS induced cell death (65; 142; 155). 
Cells have a large number of mechanisms in place to deal with reactive oxygen 
species. Antioxidant enzymes such as superoxide dismutase, glutathione reductase, 
and others scavenge free radicals. Systems such as the glutathione and thioredoxin 
systems assist in scavenging ROS, and convert ROS damaged proteins back to their 
normal conformation, while the heat shock proteins bind to damaged proteins 
preventing misfolding and aggregation. If the levels of ROS are too high for the 
cellular antioxidant systems to scavenge, then the cell will undergo apoptosis, or in 
some cases necrosis. 
To determine which pathways are affected by treatment with KLM155, we performed 
microarray analysis on treated and untreated samples. A number of genes were up 
or down regulated, and we confirmed this using real time reverse-transcriptase peR. 
Several of the genes identified are known responses to an increased level of ROS, 
and are upregulated in order to deal with the effects of ROS damage. 
4.3.3.1. Antioxidant response 
We detected the upregulation of a number of genes that encode enzymes associated 
with an antioxidant response. These included heme oxygenase 1 and thioredoxin, 
while the levels of MnSOD and glutathione reductase were unaltered. Upregulation of 
NQ01 was also observed, which may be an indication that this enzyme is indeed 
involved in the metabolism of the KLMs. 
Heme oxygenase 1 (H01) is one of a family of heme oxygenases, which catalyses 
the breakdown of heme, a constituent of many proteins. ROS modifications of heme-











(130; 156). Thus upregulation of heme oxygenase occurs to deal with increased free 
heme levels under conditions of oxidative stress (157). HOi is one of the cell's major 
activated pathways in response to oxidative stress, and its upregulation as a 
response to reactive oxygen species is the result of a number of signaling molecules, 
including APi and Nrf1 (158). 
While the induction of heme oxygenase is generally considered to be a protective 
response to ROS stress, there is some evidence that HOi induction can be a pro-
oxidant event (159;160). Since one of the breakdown products of heme is the low-
molecular mass iron, which is an extremely redox active form of iron, ferritin is 
generally upregulated in conjunction with HOi (we noted a 1.6 fold upregulation of 
ferritin in our microarray results (p 0.021». However, in cases where HOi activity is 
higher than that of ferritin, excess low-molecular-mass redox-active iron may be 
generated, and this may contribute to increasing the cellular redox stress (159). Our 
results, demonstrating exceptionally high upregulation of HOi, suggest that this may 
be occurring in our system. Further experiments would be needed to confirm this. 
Significant upregulation of thioredoxin reductase was observed in KLM155 treated 
cells. Thioredoxin reductase is a selenoprotein that reduces oxidized protein 
substrates (161), and forms part of the thioredoxin system which helps regulate the 
cellular redox balance. This system acts to mediate ROS stress in several ways. 
First, the thioredoxin molecules are easily oxidized by free radicals, and then reduced 
by thioredoxin reductase, with NADPH as an electron donor. Thus thioredoxin serves 
to scavenge ROS molecules (131). Secondly, oxidized thioredoxin translocates from 
the cytoplasm to the nucleus, where it activates the Ref1, which in turn activates a 
number of transcription factors including AP1 and NFKB. These in turn upregulate a 
number of genes which encode molecules which protect the cell from oxidative stress 
or induce apoptosis (162). 
The upregulation of thioredoxin reductase in our system is most likely a reflection of 
increase oxidized thioredoxin, and serves to reinforce our hypothesis that KLMs 
induce oxidative stress in treated cells. It seems likely that increased oxidized 
thioredoxin is one of the signaling events leading to upregulation of AP1 in our 











4.3.3.2. Repair of ROS induced damage 
DNA-damage inducible transcript 3 (GADD34) is induced in response to DNA 
damage and plays a role both in halting the cell cycle, and in repairing DNA damage 
(132). It's upregulation following KLM155 treatment is most likely in response to DNA 
damage caused by reactive oxygen species. 
The heat shock proteins play an important role in the cellular response to oxidative 
stress. By binding ROS-damaged proteins, they prevent these proteins from 
misfolding, and from forming aggregates (133). Upregulation of HSP70 can also 
prevent apoptosis by preventing the release of cytochrome c from the mitochondria, 
disruption of apoptosome formation, and prevention of procaspase recruitment (163). 
4.3.3.3. Apoptosis 
Despite the many varied responses to survive oxidative stress, in some cases ROS 
production, and the resulting damage, overwhelms the cells ability to deal with these 
events, and cells then undergo apoptosis (164). We demonstrated that KLM 155 
induces apoptosis, following production of reactive oxygen species in WHC01 cells. 
The mechanism by which KLM155 induces apoptosis in WHC01 cells has yet to be 
fully characterized, but we have shown involvement of c-Jun, and that caspase 3 is 
activated in these cells. Further work will involve examining other pathways, such as 
NFKB and Nrf in the activation of apoptosis in these cells, and determining if 
apoptosis is triggered via the mitochondrial or death receptor pathways. 
4.3.3.4. AP1 activation 
Several cellular signaling pathways may playa role in the cellular response to ROS. 
Among these are stress response pathways such as p38 and JNK. Treatment of 
WHC01 cells with KLM155 in this study specifically activated the JNK/c-Jun pathway 
and not the p38 pathway. 
We hypothesise that at low concentrations of KLM155, low levels of ROS may induce 
c-Jun (or other signaling pathways), which in turn upregulate antioxidant enzymes 











overwhelms the cell's ability to cope with the stress, and c-Jun becomes pro-
apoptotic (134; 135). 
Our results strongly implicated JNKlc-Jun signaling in mediating compound KLM1 
induced apoptosis, with upregulation of c-Jun in KLM155 treated cells, and the 
observation that the JNK inhibitor abrogated KLM155-induced apoptosis. It was quite 
intriguing that while the JNK inhibitor blocked the apoptosis induced by KLM155, this 
inhibitor had no significant effect on the reduction in cell number caused by KLM1 
(Figure 4,15.). This should be considered in the context of the results observed for 
Trolox, which blocked apoptosis to the same extent as the .. INK inhibitor, but 
significantly prevented a reduction in cell number in response to treatment with 
KLM155. Presumably, the block in apoptosis caused by the JNK inhibitor occurs 
despite the ROS-induced cellular damage inflicted by treatment of cells with KLM155. 
Cells may then die through non-apoptotic pathways if denied access to apoptosis, as 
described before (165). The ability of both Trolox and BHA to block apoptosis and the 
ability of Trolox to decrease the reduction in cell number caused by treatment with 
KLM155, reflects the proximal site of action of these ROS scavengers, allowing them 
to protect cells from extensive ROS-induced damage, and thus precluding the 
requirement for apoptosis. 
The role of ROS in activating ...INK (an important upstream activator of c-Jun) through 
the inactivation of endogenous JNK inhibitors has already been documented, 
providing a plausible pathway for the induction of c-Jun observed here. Oxidation of 
thioredoxin causes it to translocate to the nucleus where it interacts with Ref-1, 
facilitating the Ref-1 mediated reduction of a cysteine residue in the DNA binding 
domain of fos and c-Jun, causing an increase in DNA binding and transactivation of 
these molecules (166; 167), ROS also affects AP1 activity indirectly, again through 
thioredoxin. Under normal cellular conditions, reduced thioredoxin is bound to ASK 1. 
a MAPKKK upstream of both JNK and p38 signaling pathways. Oxidation of 
thioredoxin causes it to dissociate from ASK1, allowing ASK1 to activate the JNK and 











4.3.4. Production of ROS as a chemotherapeutic strategy 
Cancer cells generally are exposed to much higher levels of oxidative stress than 
normal cells (67), This is based on direct measurements of ROS levels in tumour 
tissues (168), accumulation of oxidative products in tumour tissue (169), and the 
presence of oxidised DNA products in the urine of cancer patients (170), Of 
particular interest for this study, elevated levels of SOD measured in squamous cell 
carcinomas of the oesophagus relative to normal tissues, suggest that oesophageal 
tumour tissues are also under increased oxidative stress (171). As a result of the 
constant assault of oxidative stress, cancer cells have an impaired ability to combat 
oxidative stress (relative to normal cells) rendering them sensitive to additional 
oxidative challenges. This diminished ability of cancer cells to mount an effective 
response to further oxidative challenges may represent a critical therapeutic window 
that could be exploited to develop more selective anticancer agents (61 ;67). The 
central role of ROS in mediating the cytotoxic activity of the family of 
triprenylquinones and triprenylhydroquinones described here underscores the value 
of this novel family of compounds as potential lead chemotherapeutic agents for 












This chapter describes the anticancer activities of a family of novel compounds of 
triprenylquinones and triprenylhydroquinones (Figure 3.2.) isolated from the 
nudibranch L. mil/eera (Figure 3.1.) collected from Algoa bay, South Africa (95). 
In Chapter 3 we demonstrated the ability of these compounds to cause cell death 
and inhibit proliferation in oesophageal cancer cells. We have further shown that the 
activity of these compounds was directly associated with their ability to generate 
ROS. Firstly, we were able to directly measure ROS production in celis treated with 
these agents, secondly, there was a strong inverse correlation between the IC50 
values of the compounds tested, and ROS production, and lastly, treatment of cells 
with the ROS scavengers BHA and Trolox reduced the extent of apoptosis caused by 
treatment with KLM155 (Figure 4.5.). We were able to demonstrate the induction of 
several antioxidant response molecules including heme oxygenase 1, thioredoxin 
reductase, GADD34 and HSP70. Increased signaling through the JNK MAPK 
pathway was detected, and this plays a role in apoptosis induction, since treatment 
with a JNK inhibitor was able to block apoptosis in KLM155 treated cells. 
The strong correlation between the levels of ROS produced by each of the 
compounds and their ICso's, and the structural similarity of the family of compounds 
described here provide an exciting opportunity to further explore the structural 
elements that confer activity in these molecules. This study and others (172-176) 
supports the contention that marine benthic organisms from the coast of southern 
Africa represent a rich, untapped repository of novel and interesting compounds that 














The objectives of this study were as follows' 
1. Establish a screening program, similar in approach to the NCI 60-cell line 
screen, using oesophageal cancer cell lines to identify compounds that may 
be of use as chemotherapeutic agents for this cancer. 
2. Screen marine extracts, and supply cytotoxicity data to assist with activity-
directed fractionation of active compounds. 
3. Identify novel compounds active against oesophageal cancer, and assess 
their mechanism of action. 
5.2. Novelty of the approach 
The work described in this thesis is novel in the following respects: 
1. The cell line used as a primary screen in this study (WHC01) is derived from 
oesophageal cancer tumour tissue, and thus is ideal to identify compounds 
that may be effective against oesophageal cancer. 
2. The extracts and compounds used in this study are from organisms collected 
from the southern African coast. Many of the extracts tested were from 
previously unidentified organisms, and in some cases from newly identified 
endemic species, and thus we had access to completely novel source 
organisms, and compounds. 
3. The group of triprenylquinone and hydroquinones identified for further 
characterization are derived from an organism endemic to the South African 
Coast, and are unique. We have searched the literature, and found very few 
similar compounds that have been tested for activity against cancer cells, and 











5.3. Key findings 
We established a screening program to identify agents active against an 
oesophageal cancer cell line. This screen is cheap, rapid (less than a week), and has 
the capacity to be expanded to include cell lines derived from other cancers of clinical 
significance in South Africa. 
Using this screen, we tested a total of 479 samples. The capacity of this screen is far 
higher, but the number of samples tested was restricted by the supply. At full 
capacity this screen could test 50-100 compounds per week using just one 
researcher. 
Our screening of (175 extracts) extracts from marine organisms confirmed previous 
findings that sponges are the organisms most likely to yield bioactive metabolites. 
We also identified 5 samples for activity-directed fractionation, which gave rise to a 
total of 15 compounds with varying activity against oesophageal cancer cell lines. 
The aim of this project was not simply to identify active compounds, but also to 
identify pathways and systems activated by these compounds as they caused cell 
death. To this end a group of triprenylquinones and hydroquinones was identified as 
suitable for further characterisation. 
We determined that these compounds are cytotoxic to a number of cancer cell lines, 
and further, that the mode of cell death was via apoptosis, and not necrosis. These 
compounds exerted their effects by the generation of reactive oxygen species, and 
signaling via the stress response JNK MAPK pathway. Microarray analysis of treated 
cells confirmed the oxidative stress response, with a number of genes involved in 
antioxidant defense being upregulated following treatment with one of these 
compounds. 
The production of ROS has been implicated in the action of many chemotherapeutic 
agents, and presents a sound strategy for treatment of tumours. There is increasing 
evidence that tumour cells are under increased oxidative stress, and the generation 












5.4. Difficulties encountered in this project 
5.4.1. Scarcity of supply 
During the course of this project, we identified several extracts from marine 
organisms that were active against our screening cell line, but were unsuitable for 
activity-directed fractionation due to the low quantities of sample. 
In some cases (such as makaluvamine I), a compound was identified from an active 
extract, but in such minute quantities that there was insufficient compound to assess 
its activity against the screening cell line. 
Our work determining the mode of action of the KLM compounds was limited since 
we had relatively small quantities of each compound to work with. In order for these 
compounds to be validated as potential chemotherapeutic agents, further 
experimentation would be required, including pharmacological testing and in vivo 
tumourigenicity assays in mice. This would require much larger amounts of 
compound than is currently available, and if the compounds were to enter clinical 
trials, even greater amounts would be required. Thus establishing a sustainable 
supply of these compounds is a critical point in their potential development as 
chemotherapeutic agents. Our collaborators at Rhodes University have already 
embarked on a program to synthesise the KLM compounds, and larger amounts of 
these compounds will soon be available for more extensive biological studies. 
5.4.2. Increasing complexity at each stage in the drug discovery process 
While our screening assay is relatively rapid (4 days), and is capable of screening 
large numbers of samples, the following processes of chemical purification and 
elucidation of structures are labour intensive, and time consuming. 
Finally, elucidating the mechanism of action of a compound or group of compounds 
is even more time consuming, 
The increasing research effort required at each stage in this process is evidenced by 
the number of extracts screened (175), which led to only 5 activity-directed 
fractionations, identifying 15 compounds, and in the duration of this project, only one 











increased amount of effort and expense at each stage in the drug development 
process. 
5.5. Future directions 
5.5.1. Screening assay 
It was our intention in establishing this screening assay to identify potential 
chemotherapeutic agents for the treatment of oesophageal cancer. However, the 
assay has the potential to be expanded to include other cell lines. For example, we 
could include a cervical cancer cell line, to identify agents that may be of use in 
treating cervical cancer, the most common cancer affecting women in South Africa. 
During the course of this project, our collaboration with the Department of Chemistry 
at Rhodes University gave us access to a wide selection of marine extracts and 
compounds, and this has been the focus of this thesis. However, compounds from 
other sources could be tested in this assay, and in fact, we have established a 
collaboration to synthesise and test novel organometallic compounds with the 
Department of Chemistry at the University of Cape Town. 
Of the samples screened, we observed an unusually high rate of activity in samples 
from Marion Island. It may be advisable to hold another collection at this location to 
confirm this finding. 
5.5.2. KLM compounds 
5.5.2.1. SyntheSiS of the KLMs and analogues 
While the current low supply of compounds prevents much further work on the KLMs, 
our collaborators are currently in the process of synthesizing these compounds and 
analogues. In the future we hope to be able to assess the contribution of the triprenyl 
side chain, and altered substitution on the ring on the activity of these compounds. It 
is also important to validate the results observed for KLM155 for the other 
compounds. Once sufficient quantities of KLMs are available we are considering 
submitting these for the NCI 60 cell line screen as this will provide further information 
as to the suitability of these compounds for the treatment of a wide range of cancers, 













Further elucidation of the molecular events occurring in KLM 
We also intend to elaborate further on the mechanism by which KLM155 induces 
apoptosis. We identified the JNK MAPK pathway as being activated, but the 
molecular events leading to this activation were not explored. The microarray results 
suggest the involvement of thioredoxin, but other signaling pathways are activated by 
ROS and may be involved in the antioxidant and cell death response to KLM1 
treatment. Our determination that cell death occurred via apoptosis centered around 
the detection of the activated effector caspase 3. While this is a good indication that 
apoptosis is occurring, it is the point at which signaling via the mitochondrial and 
death receptor apoptosis pathways intersect. We intend to establish which of these 
pathways is activated in response to KLM155 treatment. Determining the signaling 
and apoptosis pathways induced by KLM treatment may be important in monitoring 
patient responses to treatment, and in determining drug combinations, should these 
compounds enter clinical trials at some point in the future. 
An important consideration in the assessment of the KLMs as suitable drug leads 
would be to determine the activity of these agents in mouse xenograph studies or the 
NCI in vivo hollow fibre studies. We plan to submit these compounds for these whole 
animal studies as soon as sufficient quantities are available. 
5.5.2.3. Determine the involvement of NQ01 in the action of the KLMs 
We hypothesise that NQ01 plays a role in activating the KLM quinones. We intend to 
evaluate the role of N001 in metabolizing the KLMs and producing ROS. First, we 
need to conclusively show that KLM quinones are metabolized by NQ01. This can 
be determined using pure NQ01 and compounds, and then determining the levels of 
the parental quinone and corresponding hydroquinone by HPLC. If N001 does play 
a role in activating the KLM quinones, it may be possible to rationally design even 
more effective KLMs using the known crystal structure of NQ01. 
Should N001 be involved in activating the KLM quinones, we would determine the 
level of NQ01 in oesophageal tumour tissue. Previous studies have shown elevated 
levels of NQ01 in a variety of tumours. Should NQ01 prove to be upregulated in 
oesophageal tumours, it would indicate the potential for differential activity of the 











5.5.3. ROS production as a therapeutic option 
This study and others have shown the potential of agents that produce ROS to kill 
cancer cells. It may be informative to elaborate on this by assessing the levels of 
antioxidant enzymes in tumour tissue compared to normal by both quantitative real-
time RT-PCR and immunohistochemistry. Should we show that oesophageal 
tumours have low levels of antioxidant enzymes, it may suggest new therapeutic 
options for these patients. 
5.6. Conclusion 
Both the screening program and the group of compounds described in this thesis 
have the potential to give rise to promising drug leads that can be further developed 












MATERIALS AND METHODS 
Unless otherwise mentioned, all chemicals were AnalR grade, and purchased from 
Sigma or Merck. Recipes for all solutions mentioned are listed by experiment in 
Section 6.14. of this chapter. 
6.1. Cell culture 
All cell lines were maintained at 3rC, in a 5% CO2, humidified incubator. 
6.1.1. Cell lines and medium requirements 
The human oesophageal cancer cell lines designated WHCO (WHC01, WHC03, 
WHC05, WHC06) were obtained as a generous gift from Prof R. Veale, University of 
the Witswatersrand, South Africa. These cell lines were derived from South African 
patients with squamous cell carcinoma of the oesophagus (83). 
The human oesophageal cancer cell lines designated KYSE were obtained as a 
generous gift from Prof Y. Shimada, Kyoto University, Japan. These cell lines were 
derived from Japanese patients with squamous cell carcinoma of the oesophagus 
(177). 
SiHa cells (ATCC HTB-35) (178) and ME180 cells (ATCC HTB-33) (179), both 
cervical cancer cell lines, were obtained from Dr. M. Birrer, National Institute of 
Health, USA. 
MCF12A cells (ATCC CRL-10783) are a breast epithelial line cultured from a non-
malignant growth (89), and were obtained from Prof. M.1. Parker, University of Cape 
Town, South Africa. 
The CaskiITAM67 cell line and the parental Caski cell line were obtained from Dr. V 
Leaner, University of Cape Town, South Africa. The Caski cell line is a cervical cell 











































Table 6.1. Cell lines and medium requirements. 
6.1.2. Subculturing protocols 
Antibiotics 





















10 fj9/ml insulin 
All cell lines were subcultured by removing medium, rinsing once with 2 ml PBS (or 
0.5% trypsin in PBS), then trypsin ising with 3 ml trypsin. Once cells had rounded, 3 
ml of medium were added to neutralize the trypsin, and cells were centrifuged out of 
the trypsin:medium mix. Cells were then resuspended in the appropriate medium and 











6.1.3. Freezing and thawing protocols 
For all cell lines, a confluent dish was trypsinised, neutralized with complete medium, 
then cells were centrifuged out of the trypsin/medium solution. Cells were 
resuspended in 3-4 ml of freezing medium (90% complete culture medium, 10% 
DMSO), and aliquated into cryotubes (1 ml per tube). Tubes were placed in -70 D C 
overnight and then transferred to liquid nitrogen. 
6.1.4. Mycoplasma test 
All cell lines were tested for mycoplasma contamination every three months. Cells 
were grown in culture medium free of antibiotics for at least one week, then 
trypsinised and plated onto coverslips in 60 mm dishes. Following an overnight 
incubation to allow cells to settle onto coverslips, 5 ml fixative was added to the 
culture medium, then discarded and replaced with another 2.5 ml fixative. The cells 
were then immediately washed gently with water and dried by inversion. Once the 
coverslip was dry, mycoplasma staining solution was added for 30 sec and then 
thoroughly washed with water. Finally the coverslip was mounted on a slide, using a 
drop of mounting fluid, and cells were observed using fluorescence microscopy. Cell 
nuclei stain bright green, and mycoplasma c ntamination is visualized as minute 
punctate fluorescence distributed throughout the cytoplasm (180). 
6.2. Screening 
6.2.1. Crystal violet assay 
Initial screening for cytotoxicity was carried out as described previously (176) by 
plating cells at 1500 cells/well in 90 IJI DMEM in CellStar 96 well plates. After 24 
hours incubation to allow cells to settle, test compounds were added in 10 IJI DMEM 
to a final concentration of 1, 10 and 50 1J9/ml, with solvent (DMSO) at 0.2%. 
Following 48 hours incubation, observations of cell number and morphology were 
made, and the plates were then processed for crystal violet staining as follows (88). 
Medium was discarded, the plates allowed to drain, and cells were fixed by adding 
100 IJI methanol to each well. Following a 10 min incubation, the methanol was 











min. Plates were washed thoroughly under running water, and the remaining stain 
was solubilised using a 50% acetic acid in water solution . Plates were read at 595nm 
on an Anthos microplate reader 2001 (Austria). 
Controls on each plate included a no-cell (medium only) blank, and untreated cells as 
a 100% control. 
6.2.2. Analysis - scoring system 
Samples which did not decrease cell number at any concentration were given a 
score of 0 (e.g. A); samples which decreased cell number to below 10% of untreated 
at the highest concentration only were scored as 1 (e.g. 8); those that decreased cell 
number to below 10% of untreated at 1 0 ~g/ml were scored as 2 (e.g. C); and those 
that decreased cell number to below 10% of untreated at the highest concentration (1 
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Samples which did not decrease cell number at any concentration would be scored 0 
(e.g. A), samples which decreased cell number to below 10% of untreated at the 
highest concentration only would be scored 1 (e.g. 8). Samples which decreased cell 
number at the highest and the medium concentration would be scored 2 (e.g . C), and 
samples which decreased the cell number to below 10% at all concentrations would 











6.3. MTT assay 
Samples for the MTT assay (181) were plated in 96 well plates in a final volume of 
100 iJl. MTT reagent (Roche Cat #1465007) was added at the end of the experiment 
- 10 iJl of MTT reagent was added per well, and plates were incubated for 4 hours at 
3rC. Solubilisation solution (100 iJl) was then added to each well, and plates were 
incubated at 3rC overnight. After 16 hours, plates were read at 595nm on an Anthos 
microplate reader 2001. 
6.3.1. IC 50 determination 
For IC50 determination, 1500 cells were seeded per well in 90 iJl DMEM in Cellstar 96 
well plates. Cells were incubated for 24 hours, then test samples were plated at a 
range of concentrations in 10 iJl medium, with a final concentration of 0.2% DMSO. 
After 48 hours incubation, observations were made, and plates were processed as 
described above. Plates were read at 595nm on an Anthos microplate reader 2001. 
6.3.2. IC 50 data analysis 
The resulting dose-response curve was analysed by non-linear regression analysis 
(l\Jon-linear regression (Sigmoidal dose resp nse with variable slope» using 
GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego 
California USA, www.graphpad.com) to yield an IC50 value which is specific for the 
compound against the particular cell line. The formula used is as follows: 
(top-bottom) 
Y = bottom + (loglC50 - X) x hillslope 1 + 10 
Where Y is the absorbance reading, x is the concentration of compound, top is the 
maximum absorbance, bottom is the minimum absorbance (also the absorbance of 
the medium blank), and hillslope is the gradient of the curve. 
6.4. Cell cycle analysis 
Cells were seeded in 60 mm dishes at 0.25x106 cells per dish. Following an overnight 
settling period, compounds were added to the culture medium (to avoid the loss of 











harvested by trypsinisation (taking care to collect all washes to avoid discarding 
floating cells), resuspended in 1 ml PBS, and counted. I\line ml of ice cold 70% EtOH 
was then added to each sample, and samples were stored at -20°C for up to 2 
weeks. Cells were then centrifuged out of EtOH, rinsed several times in PBS, and 
5x106 cells/ml were incubated in 50 !-191m I RNAse A in PBS for 30 min at room 
temperature. Cell Cycle Staining solution was added to bring the cell concentration to 
1 x1 06 cells/ml, and following a 30 min incubation in the dark, cells were analysed on 
a Beckman Coulter FACS-calibur flow cytometer. Analysis of cell cycle results was 
carried out using Mod Fit 3.0 (Verity Software House). 
6.5. Apoptosis assays 
6.5.1. Flow cytometry detection 
Levels of apoptosis in cells were assessed using the Active Caspase-3 FITC mAb 
Apoptosis Kit (BO Biosciences BO Cat#550480) according to manufacturer's 
instructions. Briefly cells were grown in 60 mm dishes, and after the indicated 
treatments, were harvested by trypsinisation (collecting medium and all washes). The 
cells were fixed (using the Cytofix/CytoPerm solution provided with the kit), and 
following two washes (with PermlWash buffer, also supplied with the kit), cells were 
stained for 30 min (protected from light) at r om temperature. Cells were washed 
again, and then resuspended in PermlWash buffer, and fluorescence was detected 
using a Beckman Coulter FACS-calibur flow cytometer. 
6.5.2. Caspase-Glo ™ 3/7 Assay 
Apotosis analysis was carried out by detecting caspase-3 activity in cells using the kit 
(Promega Cat#G8090), according to manufacturer's instructions. Cells were seeded 
at 1000 cells/well in 96 well plates in 60 fJl. Following 24 hours inCUbation to allow 
cells to settle, and in some cases a 2 hour pre-treatment with inhibitors, compounds 
were added as outlined, and cells incubated for the indicated time periods. 
Reconstituted caspase reagent was added, and following 1 hour incubation, light 











6.6. Necrosis Assay 
Analysis of the levels of necrosis was performed using the CytoTox-ONE 
Homogeneous Membrane Integrity Assay. This assay detects the release of LDH 
from cells with compromised cell membranes. LDH is detected by a coupled 
enzymatic reaction which results in the conversion of resazurin into a fluorescent 
resorufin product. Cells were plated in 96 well plates in a final volume of 90 Ill, and 
following an overnight incubation to allow cells to settle, treatments were added in 10 
III to a final volume of 100 Ill. After the desired incubation time, 100 III of Cyto Tox 
ONE reagent was added, and following a 10 min incubation, 50 III of Stop solution 
was added. At each time point Lysis Buffer (a detergent solution supplied with the kit 
which completely lysed cells, as observed by microscopy) was added to a set of 
wells as a positive control, and these were processed in the same way as the test 
wells. Fluorescence was measured on a 96-well plate fluorimeter, and values were 
expressed as a % of the positive control. 
6.7. Trypan Blue Assay 
1 x1 05 cells were seeded in 1 mllwell in 24 well plates. After an overnight incubation 
to allow cell settling, various agents were added at a 10x concentration in 110 [JI. At 
various time intervals 100 IJI of 0.4% trypan blue solution in water was added to 
duplicate wells, and the cells were incubated at 3rC for 5 min to allow uptake of the 
dye into non-viable cells. Medium and stain solution were then removed, and the 
cells washed twice with 2 ml PBS, and then observed using light microscopy. 
6.8. Reactive Oxygen Species measurement 
Cells were plated in 60 mm dishes at 5x105 cells per dish. Following 24 hours to 
allow cells to settle, medium was removed, and cells rinsed with 1 ml 3rC Krebs-
Ringer (KR) buffer, and 2 ml 25 IlM DCF-DA (Sigma Cat#D6883) in KR buffer was 
added, Following 15 min incubation at 3rC, 5% CO2 in the dark, 200 1-11 of 11 x stock 
solution of test compound was added, and cells were incubated for another hour, or 
for the indicated time at 3rC, 5% CO2. Cells were then harvested using 0.5% trypsin 
in PBS (collecting all washes and incubations). neutralizing trypsin by adding 200 IJI 
fetal calf serum to each sample, centrifuged and resuspended in 1 ml KR buffer. 
Cells were then analysed by flow cytometry on a FACS-Calibur flow cytometer, set to 











6.9. Western blotting 
6.9.1. Protein harvest 
Cells in 60 mm dishes were treated at the appropriate concentration, and for the 
indicated times. Medium was removed, cells rinsed with 1 ml PBS, and rinses and 
media were centrifuged (1000rpm, 5 min) to pellet floating cells. RIPA buffer (200 IJI) 
with protease inhibitor (Roche Complete tablets Cat#1169749800 1), made up as 10x 
stock) was added to the dish, and cells were lysed manually using a rubber 
policeman or disposable 1 ml insulin syringe plunger. The pellet of floating cells was 
taken up in the resulting lysate, and Iysates were stored at -20°C. 
6.9.2. Protein quantitation 
Lysates were thawed and sonicated at 4°C. Protein quantitation was performed in 96 
well plates using the BCA kit (Pierce). Various volumes of lysate (to a total volume of 
10 IJI) were pi petted into each well in duplicate, and made up to 10 fJl with RIPA 
buffer. Ten fJl of each BSA standard (range 10 fJg/ml to 2000 fJg/ml) were pipetted in 
duplicate for a standard curve, and 10 fJl of RIPA was included as a blank. Reagent A 
and Reagent B from the kit were mixed at a 1 :50 ratio, and 100 fJl of this solution was 
added to each well. Following a 30 min incubation at 3rC, the absorbance at 595nm 
was measured on an Anthos microplate reader 2001. A standard curve was plotted 
using Prism, and sample concentrations were calculated from this curve. 
6.9.3. SDS-PAGE 
10% Acrylamide gels with 5% stacking gel were poured using the Protean II minigel 
casting apparatus (BioRad). Protein samples were prepared by mixing equal 
amounts of protein with loading dye, and boiled for 10 min to denature proteins. 
Samples were loaded onto the SDS-PAGE, and the gel was run at 100 volts, for the 
appropriate times (depending on the size of the protein of interest). Migration of 
proteins through the gel was monitored by loading a multicolour protein ladder 












SOS-PAGE gels were removed from between the glass plates, and the transfer 
apparatus was assembled. Protein was transferred from the gel onto Hybond™-
Eel ™ nitrocellulose membrane (Amersham RPN2030), and these were sandwiched 
between filter paper and sponges, and inserted into a transfer cassette. The cassette 
and an ice pack were inserted into the transfer apparatus, which was filled with 
transfer buffer, and transfer was carried out at 200 volts for 1 hour. 
6.9.5. Ponceau S (membrane) and Coomasie (gel) stains 
Following transfer, membranes were stained with Ponceau-S (Sigma, P3504) for 10 
min, then destained with dH20 to assess protein loading and transfer efficiency. 
Ponceau-S stained membranes were photocopied. Gels were stained, then 
destained and dried as a permanent record of protein loading. 
6.9.6. Washes, blocking and primary antibody 
Following Ponceau-S staining, membranes were washed with TBS/0.1 % Tween, and 
then blocked in blocking solution (Table 2), Blocking solution was discarded, and the 
membrane was then washed with TBS/O. 1 % Tween, with shaking for three sets of 5 
min, changing TBSfO.1 % Tween each time. Primary antibody was added at the 
appropriate dilution, and in the indicated buffer (Table 2), and incubated with shaking 
overnight at 4°C. 
-.-" .. ,~---
Antibody number Dilution Diluted in Source 
~~.~-.---.. --.--.~ 
c-Jun 1 in 500 
5% fat free milk in Rabbit 
TBS/0.1 % Tween ___ P~lY~!2'laJ_ 
p-p38 Cell 
#9211 1 in 1000 TBS/0.1 % Tween 
Rabbit 
(Ib~1§9-'I~8~2 .poly<::Ic:JI1ClJ . 
ERK sc-154 1 in 1000 
2.5% fat free milk in Rabbit 
TBS/0.1 % Tween 
Table 6.2. Antibody details and dilutions 
6.9.7. Secondary antibody 
The primary antibody was removed from the membrane, and the membrane was 
again washed for three sets of 5 min, changing TBS/0.1 % Tween each time. The 











5% fat free milk in TBS/0.1 % Tween at a 1 in 5000 dilution, and the membrane was 
incubated with shaking for one hour at room temperature. The secondary antibody 
was removed, and a final set of three 5 min washes with TBS/0.1 % Tween were 
performed to remove excess antibody. Detection reagent (KPL Lumiglo Reserve) 
was added, and light emission was detected on X-ray film (AGFA). The bands were 
visualized by developing the film in developer (AGFA G128) for 1 min, washed for 1 
min with water, then fixed for 5 min in fixiative (AGFA G333C) as recommended by 
the manufacturer. 
6.9.8. Stripping Western Blot membrane 
After detection, membranes were stripped, as follows. Twenty ml 1 M glycine (pH 
2.5) was added to the blot, which was then shaken for 5 min on each side. The 
solution was neutralized by the addition of 2 ml 1 M Tris pH 7.5, and the blot was 
washed several times with TBS/0.1 % Tween and reprobed for other proteins. 
6.10. RNA isolation 
6.10.1. Trizol extraction 
1x106 cells were plated per 100 mm dish, and allowed to grow for 2 days before 
compounds were added. After the indicated times, RNA was harvested using Trizol 
reagent (Invitrogen, Cat# 15596-01S). Media was removed, and centrifuged to pellet 
floating cells. The pellet was taken up in 500 ~I Trizol and transferred to the plate, 
and an additional 700 ~I (final volume 1.2 ml) Trizol added to each plate. This was 
left to incubate for 5 min at room temperature before Trizol was transferred to an 
eppendorf tube. Chloroform (240 ~I) was added, and samples were shaken, then 
incubated on ice for 10 min. Following centrifugation at 8000 rpm for 15 min at 4"C, 
the aqueous phase was transferred to a new tube, 600 ~I isopropanol was added, 
and samples were left to precipitate overnight at -20°C. They were then centrifuged 
at SOOOrpm for 30 min at 4"C, and the pellet was washed with 1.2 ml 75% ethanol, 
centrifuged again and ethanol removed. The pellets were airdried, resuspended in 
200 1-11 DEPC H20 and transferred to a new tube. Isopropanol (200 1-11) and 20 1-11 3 M 
sodium acetate were added, and samples were precipitated at _20DC for an hour, 
then centrifuged at 15000 rpm for 30 min. Another wash with 70% ethanol was 
performed, and then the ethanol was removed, and the pellet airdried and 












RNA was quantitated spectrophotometrically by diluting the RNA solution 1 in 250 
and reading the UV absorbance at 260nm and 280nm. The concentration of RNA 
was calculated using the following equation (extinction coefficient for RNA = 40) : 
[RNA] = OD260nm X 40 X dilution factor (pg/ml) 
The purity of the RNA was tested using the following condition : 
Ratio OD26onm/OD28onm > 1.8. 
RNA quality was evaluated by electrophoresing -2 I-Ig of RNA on a formaldehyde gel. 
6.10.3. Formaldehyde gel electrophoresis 
Approximately 2 I-Ig of each sample of RNA was run on a formaldehyde gel to check 
RNA quality. One percent agarose was dissolved in 1 x MOPS solution, and allowed 
to cool to touch. 5.4 ml of 37 % formaldehyde and 5 1-11 EtBr were then added, and the 
gel poured into the casting tray. Once the gel had set, RNA samples were loaded in 
10 1-11 of RNA loading buffer, and the gel was electrophoresed in 1 x MOPS until 18S 
and 35S bands could be visualized and resolved under UV light. 
untreated 20l-lM KLM155 
a b c abc 
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Figure 6.2. Formaldehyde gel electrophoresis of RNA samples 
used for microarray and real-time RT -peR analysis. 
RNA samples for each treatment condition were electrophoresed on a 
formaldehyde gel to assess RNA quality. (a,b,c are experimental 












The microarray format was a eDNA slide. These 11000 element arrays are produced 
by the National Cancer Institute (NCI) Microarray facility using Incyte Genomics 
UniGEM clones, and were obtained from Dr. V. Leaner (University of Cape Town, 
South Africa), and Dr. M. Birrer (National Institute of Health, USA). 
6.11.1. First strand synthesis 
1 fJl of T7-(dT) primer (5'-GGCCAGTGAATTGAATACGACTCACTATAGGAGGCGG-
(dTh4-3', Genset Corp) was hybridized to 5 fJg total RNA at 70°C for 10 min in a total 
volume of 9 fJl, then cooled on ice. The reaction mix was prepared as follows: 
4 fJl first strand buffer (Invitrogen) 
2 jJl 0.1 M OTT (Invitrogen) 
2 fJl 10 mM dNTP (Gibco 18090-019) 
1 fJl RNAsin (Promega N2515) 
1 tJl1mpromp-11 Reverse transcriptase (Promega A3802) 
9 fJl RNA + T7-(dT) primer (from above) 
First strand synthesis was then carried out at 42"C for 2 hours, and the product 
placed on ice. 
6.11.2. Second strand synthesis 
Second strand reaction mix was prepared as follows: 
91 jJl sterile ddH20 
30 IJI second strand buffer (Invitrogen) 
3 jJl 10 mM dNTP mix (Gibco #18090-019) 
4 jJl E. coli DNA polymerase I (Gibco # 18010-025) 
1 tJ1 E. coli DNA ligase (Gibco #18052-019) 
1 tJl coli RNAse H (GibcD #18021-014) 
This was added to the product of first strand synthesis for a final volume of 150 tJl, 
and incubated at 16°C for 2 hr. The product was then blunt ended by adding 1.5 III (x 











The reaction was stopped by the addition of 10 IJI 0.51\/1 EDTA, and 10 1J11M NaOH, 
and incubated at 65°C for 10 min, following which 25 fJI1M Tris-HCI (pH 7.5) was 
added. 
6.11.3. DNA clean up 
DNA was purified using Phase Lock Gel™ Tubes (Eppendorf #0032007.953) as 
follows. Tubes were centrifuged at maximum speed for 30 sec. Sample was mixed 
with the lower phase of phenol:chloroform:isoamyl alcohol saturated with Tris-
HCI/EDTA (Ambion #9732), mixed, and transferred to Phase Lock Tube, then 
centrifuged at maximum speed for 2 min. The aqueous supernatant was transferred 
to a new tube, and 1 IJI linear aerylamide (Ambion #9520) added. Ninety-six fJl M 
ammonium acetate (Sigma #A2706) and 700 IJI 95 % ice cold ethanol were added, 
the pellet vortexed and centrifuged at maximum speed at 4°C for 20 min. The pellet 
was washed twice with 80 % ethanol, airdried and resuspended in 16 IJI sterile 
ddH20. 
6.11.4. Transcription 
In vitro transcription was carried out using the T7 Megaseript kit (Ambion #1334), The 
reaction mix was prepared as follows: 
4 IJI 10x reaction buffer 
4 IJI ATP solution 
4 1-11 CTP solution 
41-11 GTP solutio  
4 lJi UTP solution 
4 IJI enzyme mix 
Reaction mix was added to each sample for a final volume of 40 IJI, and samples 
were incubated at 3rC for 6 hours. DEPC treated H20 (100 1-l1) was added to each 
sample to a final volume of 100 IJI. 
6.11.5. RNA clean-up 











350 IJI Buffer RL T (containing 1 % ~-mercaptoethanol added fresh) was added to 
each sample, and the sample was thoroughly mixed. Two hundred and fifty IJI 96 % 
ethanol was added, and the sample mixed by pipetting. The sample was then applied 
to an RNeasy mini column placed in a 2 ml collection tube and centrifuged at 8000 xg 
for 15 sec. The flow through and collection tube were then discarded, and the column 
transferred onto a new collection tube. Five hundred 1-11 of 1 x buffer RPE was then 
added to the column and centrifuged again at 8000 xg for 15 sec, and the flow 
through discarded. Another 500 IJI of RPE was added and the column centrifuged till 
dry (approx 2 min) at 8000 xg. The column was then transferred into a 1.5 ml 
collection tube and 30 1-11 RNAse-free water pi petted onto the membrane, and the 
tube centrifuged for 1 min at 8000xg. 
The RNA was then quantitated as above. 
6.11.6. Labelling (Probe preparation) 
5 IJg of amplified RNA (and 5 IJg of human reference RNA (Stratagene) for each 
sample) was placed at 65°C for 5 min, then made up to 19 IJI with ultrapure H20 and 
2 IJI random primers (Gibco #48190-011). Samples were incubated at room 
temperature for 10 min. Labeling mixes were made up as follows (one Cy3 and one 
Cy5 mix per sample): 
8 tJl 5x first strand buffer (Invitrogen) 
2 tJl 20x low T -dNTP mix (Pharmacia #27-2035-01) 
4 IJI 0.1 M DTT (Invitrogen) 
1 tJl RNAsin (Promega N515) 
2 pllmpromp-II Reverse transcriptase (Promega A3802) 
4 tJI cy-3 or cy-5 dUTP (NEN #NEL999) 
21 IJI of mix was added to each probe, with the reference RNA being labeled with cy-
3 and samples being labeled with cy-5. Samples were incubated with gentle shaking 
for 1 hour at 42°C, and the reaction was stopped by the addition of 51-11 0.5 M EDTA 
and 10 tJI 1 M NaOH. Samples were incubated at 65°C for 15 min, then cooled to 











6.11.7. Probe clean-up 
Microcon-YM30 columns (Amicon #42410) were prewetted by adding 500 1J11x TE, 
and spinning for 5-6 min at 13000 rpm. Flow through was discarded, and columns 
were checked to ensure a thin film of TE covered the membrane. TE (300 IJI) was 
added to each sample and transferred onto a column, which were then centrifuged 
for 5-6 min at 13000 rpm. The column was then washed by adding 450 IJI TE and 
spinning as before. A clean eppendorf tube was inverted over each reference RNA 
column, and probe was eluted by spinning at 14000 rpm for 1 min. The reference 
RNA probes were then pooled and equal amounts aliquoted into each sample probe. 
TE (380 IJI) was added to each sample, and the column was centrifuged at 13000 
rpm until about 7-14 III remained on the membrane. A clean tube was inverted over 
the combined column and centrifuged for 1 min at 14000 rpm. The probe volume was 
then made up to 141J1 with and stored at 4"C. 
6.11.8. Hybridisation 
Prehybridisation buffer was prepared as follows : 
250 IJI 20x SSC 
5 1J120 % SOS 
100 IJI 100 mg/ml BSA (Sigma B4287) 
645 IJI ddH20 
The hybridization chamber was assembled as follows: 
20 1-11 ddH20 was added to each humidifying well of the hybridization chamber. The 
microarray slide was placed in the hybridization chamber, and 40 IJI prehybridisation 
buffer was added to the centre of the slide. A coverslip was placed on top of the 
prehybridisation buffer, and the cover of the hybridization chamber was firmly 
screwed in place. Following a 1 hour incubation at 42°C the cover was removed and 
the slide removed with forceps. The cover slip was allowed to fall off into ddH20, and 
the slide was washed in ddH20 for 2 min and isopropanol for 2 min. The slide was 












Fresh 2x hybridization buffer was prepared and warmed to 42°e. 
1 00 ~I 20x sse 
1 00 ~I formamide 
4 ~110 % SDS 
2 ~I eOT1 DNA (Gibco #15279-011), 2 ~I polyA (Sigma #P9403) and 2 tJl yeast 
tRNA (Sigma #R8759) were added to each sample, and samples were denatured at 
1 oooe for 1 min, then snap cooled on ice, Twenty IJI of 2x hybridization buffer was 
added to each sample to a final volume of 40 IJI, and samples were kept at 42°e 
protected from light until spotted onto the slide. 
The hybridization reaction was set up in the same way as the prehybrldisation 
reaction, only with sample replacing the hybridization buffer. The slides were then 
hybridized for 16 hours at 42°e protected from light. 
6.11.9. Slide washes 
The slide was removed from the hybridization chamber, and the coverslip was 
removed by dipping in a 2x sse, 0.1 % SDS solution. The slides were then washed 
in 1 x sse, 0.1 % SDS for 4 min, 0.2x sse for 4 min, and 0.05x sse for 1 min, then 
centrifuged at 705 rpm for 4 min or until dry. 
6.11.10. Data acquisition 
Slides were scanned on a 1 0 ~m resolution GenePix 4000 scanner (Axon 
Instruments), and images were saved in TIFF format. 
6.11.11. Data analysis 
The array TIFF images were analysed using GenePix software v3.0 (Axon 
Instruments). Result files were exported into the Nel microarray database (MaDB) 











6.12. Quantitative RealMtime RT -peR 
6.12.1. Reverse transcription I cDNA 
1 IJI of T7 -( dT) primer (5'-GGCCAGTGAA TTGAA TACGACTCACTA TAGGAGGCGG-
(dTh4-3', Genset Corp) was hybridized to 5 IJg total RNA at 70 c C for 10 min in a total 
volume of 91-11, then cooled on ice. The reaction mix was prepared as follows: 
4 1-11 first strand buffer (Invitrogen) 
2 1-11 0.1 M OTT (Invitrogen) 
2 IJI 10 mM dNTP (Gibco #18090-019) 
1 IJI RNAsin (Promega #N2515) 
1 IJI Impromp-II Reverse transcriptase (Promega A3802) 
9 IJI RNA + T7-(dT) primer (from above) 
First strand synthesis was then carried out at 42°C for 2 hours, and the product 
placed on ice. Samples were made up to 50 1-11 with DEPC treated H20 to a final 
concentration of 100 ng/IJI. 
6.12.2. Real Time peR 
Real Time PCR was carried out using the LightCycler FastStart DNA Master SYBR 
Green I reaction mix (Roche). Two 1-11 of cDI\lA was added to each capillary, together 
with 18 1-11 of reaction mix: 
12.61-11 dH20 
2.41-11 MgCb 
1 1-11 Hot Start reaction mix 
1 1-11 20pM sense primer 
1 IJI 20pM antisense primer 
Primers and cycle conditions used are listed in Table 6.3. 
Prior to all amplifications samples were denatured at 95°C for 5 min. Melt curves 
were performed on all samples after each amplification to confirm the presence of a 















forward 5'-GAGGGAAGCCCCCACTCA-3' 40 cycles of 
oxygenase 
95°C (15sec) 
reverse 5'-AACTGTCGCCACCAGAAAGCT -3' 60°C (60sec) 
forward 5' -CGACA TAGGA TGCTCCAACA-3' 40 cycles of 




reverse 72°C (30sec) 




53 Q e (60sec) 
noe (30sec) 
forward 5' -TCAA TTTGCAGA TGGCCAGCGTGCTCC-3' 
45 cycles of 
95°C (1sec) 
GADD34 58 D e (10sec) 
reverse 5' -CCTCGGCTTTCTCCTCCCCTGGGTTCTT AT -3' nee (6sec) 
62"e (6sec) 




58 ae (30sec) 
72 a e (30sec) 
forward 5'-GA T AAACCCTGACCA TTCC-3' 
45 cycles of 
95°C (15sec) 
HSP90 60°C (45sec) 
reverse 5' -TTT A TGAAACTGCGCTCCTGTCTT -3' 72
e e (10sec) 
82°C (1sec) 
forward 5'-GGAGGCGGAGAAGTACA-3' 45 cycles of 
HSP70 
95°C (15sec) 
reverse 5'-GCTGATGATGGGGTT ACA-3' 
60°C (60sec) 
noe (10sec) 






forward 5' -TTAGGAA T AACCAGCGA TGGA TTT -3' 45 cycles of 
GlutathIone 95°C (1 
reductase 
5' -AA TGTAACCTGCACCAACAA TGA-3' 
60"e (60sec) 
reverse 72°C (10sec) 











Several quantitation methods exist for real-time RT-PCR analysis. We chose to use 
the 2-MCT method (129). The CT (threshold cycle) value for GAPDH for each sample 
was subtracted from the CT value obtained for that sample for the gene in question 
(ACT). Then one sample was chosen as a reference, and the ACT value for this 
sample was subtracted from the ACT for each of the other samples. This gave the 
AACT value for each sample, with the reference having a value of O. The fold 
upregulation over the reference was then calculated as 2~MCT. This gives a value of 1 
for the reference sample. Finally the 3 treated samples were averaged, and divided 
by the average of the untreated samples to give a fold upregulation, with a 
significance value attached. 
Fold upregulation = 2·MCT 
CT values CT values 
ACT ALlCT 
Fold 
(sample gene) (reference gene) upregulation 
A 0 A-O (a) a-a 2-(a·aj 
B E B-E (b) b-a 2-(b·a) 
C F C-F (c) c-a 2·(c·a) 
Table 6.4. Example of the 2-MCT calculation. 
6.13. Data analysis 
In all cases, unless otherwise indicated, error bars indicate standard deviation. 
For ROS determination, each experimental condition was carried out in triplicate, and 
results are the mean ± SD and are representative of 2 or more independent 
experiments. 
Apoptosis experiments were carried out in quadruplicate, and results are the mean ± 
SO, and are representative of 2 independent experiments. 
Cell growth and death determinations were carried out in quadruplicate, and results 
are the mean ± SO and are representative of 2 or more independent experiments. 
Each concentration for IC50 determination was tested in quadruplicate, and each IC50 
was repeated at least twice. 











6.14.1 Cell culture 
Trypsin-EDT A 
0.5 9 trypsin 
8 9 NaCI 
1.45 9 Na2HP04.2H20 
0.2 9 KCI 
0.2 9 KH2P04 
10 mM EDTA (pH 8.0) 
In 1 L PBS 
PBS 
1 mM NaCI 
2.7 mM KCI 
4.3 mM Na2HP04.7H20 (pH 7.4) 
1.4 mM KH 2P04 
Penicillin/streptomycin solution 
143 
Add 5 million units Penicillin G Sodium (Highveld Biological) to 5 ml PBS. 
Add 5 9 214S Streptomycin Sulphate (Highveld Biological) to 15 ml PBS. 
Combine the two and make volume up to 500 ml. Aliquot 5 ml volumes. 
Add 5 ml to each 500 ml media. 
Mycoplasma detection fixative 
1 part glacial acetic acid to 3 parts methanol 
Mycoplasma detection Stain solution 
0.5 jJg/ml Hoeschst No. 33258 in Hanks Buffered Saline Solution (without phenol red 
or sodium bicarbonate) 
Hanks Buffered Saline Solution (without phenol red or sodium bicarbonate) 
5.4 mM KCI 
0.3 mM Na2HP04 










1.3 mM CaCI2 
0.5 mM MgCI2 
0.6 mM MgS04 
137 mM NaCI 
5.6 mM D-glucose 
Make up to 1 L with dH20 and pH to 7.4 
Mycoplasma detection Mounting Fluid 
1.05 9 citric acid 
1.41 9 Na2HP04.2H20 
50 ml glycerol 
144 
pH 5.5 (check periodically - critical for optimum fluorescence) 
6.14.2. Crystal violet assay 
Crystal violet staining solution 
1 % crystal violet 
50 % MeOH 
6.14.3. Cell Cycle analysis 
Staining solution 
0.1 % Triton Xi 00 
2 mM MgCI2 
100 mM NaGI 
0.01 M PIPES buffer 
1 0 ~g/ml propidium iodide 
6.14.4. ROS assay 
Krebs-Ringer buffer 
110 mM NaGI 
2.6 mM KCI 
1.2 mM MgS04 
1.2 mM KH 2P04 
25 mM NaHG03 











Dissolve in water, pH to 7A, then make up to 1 L. 




150 mM NaCI 
Western blotting 
1 % Triton X100 
0.1 % SDS 
10 mM Tris (pH 7.5) 
1 % deoxycholate 
Protease inhibitor 
1 Complete tablet was dissolved in 5 ml dH20 to make a 10x solution. This was 
aliquated and stored at -20°C. 
30% Acrylamide 
30 9 acrylamide 
0.8 9 bis-acrylamide 
0,1 9 SDS 
Add dH20 to 100 ml and mix 
Store at 4°C 
Stacking Buffer 
5.9 9 Tris 
OA 9 SDS 
pH to 8.0 and make up to 100 ml with dH20. Store at 4°C 
Resolving Buffer 
36,2 9 Tris 
0.8 9 SDS 










5x Loading Buffer 
1.75 9 Tris 
30 ml glycine 
Make up to about 40 ml with dH20 
pH to 6.8 with 1 N HCI 
Add 5 9 SDS 
Add H20 to 50 ml 
Loading Dye 
200 fJl 5x loading buffer 
100 fJl B-mercaptoethanol 
146 
100 fJl saturated, filtered bromophenol blue 
10x Running Buffer 
40 9 glycine 
63.2 9 Tris 
10 9 SDS or 100 m110% stock 
Make up to 1 L with dH20 
Dilute 1 in 10 for 1 x running buffer 
10x Transfer Buffer 
144 9 glycine 
38 9 Tris 
Make up to 1 L with dH20 
1 x Transfer Buffer 
100 ml 10x transfer buffer 
200 ml isopropanol 
700 ml dH20 
Gel stain solution 
50 % methanol 
10 % glacial acetic acid 










Gel destain solution 
10 % methanol 
7.5 % glacial acetic acid 
Ponceau-S stain solution 
0.1 9 Ponceau S 
1 ml glacial acetic acid 
100 ml dH20 
10x Tris buffered saline (TBS) 
60.5 9 Tris 
87.6 9 NaCI 
pH to 7.5 
make up to 1 L with dH20 
TBS/O.1 % Tween 
100 ml10x TBS 
900 ml dH20 
1 ml Tween 20 
Blocking solutions 
5 9 fat-free milk powder 
Dissolve in 100 ml TBS/0.1 % Tween 
Fixer (AGFA G333C) 
147 
Dilute 100 ml stock solution with 400 ml dH20 
Developer (AGF A G128) 
Dilute 100 ml stock solution with 400 ml dH20 
6.14.6. RNA isolation 
10x MOPS 
0.4 M MOPS, pH 7.0 
0.1 M sodium acetate 












172.32 9 Sodium Chloride 
88.23 9 Sodium Citrate 
Make up to 1 L 
pH to 7.0 
10X TE Buffer 
0.1 M Tris-CI, pH 7.5 
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